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Les cellules souches mésenchymateuses dérivées de moelle osseuse (BM-MSCs) représentent 
des outils intéressants pour des applications de thérapie cellulaire et, plus particulièrement, pour 
la médecine régénératrice, au vu de leur capacité de différentiation. La différentiation cellulaire 
implique un remaniement profond de l’expression des gènes et du métabolisme, incluant un 
remodelage mitochondrial. Plusieurs observations faites précédemment dans notre équipe 
supportent une possible régulation traductionnelle, potentiellement impliquée dans le 
remodelage mitochondrial observé durant la différentiation hépatogénique des BM-MSCs. La 
régulation de l’axe eukaryotic Initiation Factor 4E (eIF4E)-Binding Protein (4E-BP1)-eIF4E 
est un régulateur majeur de l’assemblage du complexe eIF4F, régulant l’initiation de la 
traduction dépendante de la coiffe. Par ailleurs, le complexe 1 mTOR, promouvant la croissance 
cellulaire, est reconnu pour assurer la biogenèse mitochondriale via la régulation de l’axe 
eIF4E-4EBP1. 
Lors de ce travail, nous avons montré une régulation de l’axe eIF4E-4EBP1, associé avec 
l’activité de mTOR, affectant la phosphorylation de 4EBP1 ainsi que son activité de liaison aux 
facteurs d’initiation de la traduction, menant à la formation du complexe eIF4F dans les cellules 
en différentiation. Cependant, le taux de traduction dans ces cellules n’est pas augmenté lors de 
l’induction de la différentiation hépatogénique, comparé aux cellules non-différenciées, tandis 
qu’il est faiblement augmenté dans la phase tardive de maturation du protocole de 
différentiation. Dans l’ensemble, ces résultats nous ont menés à proposer l’hypothèse une 
possible régulation traductionnelle basée sur la traduction coiffe-indépendante lors de l’étape 
d’induction de la différentiation hépatogénique, supportant le remodelage mitochondrial et 
dirigeant la différentiation hépatogénique. 
 
Mémoire de master 120 en biochimie et biologie moléculaire et cellulaire    
Janvier 2019 










Bone Marrow-derived mesenchymal stem cells (BM-MSCs) represent attractive tools for cell-
based therapy and more particularly for regenerative medicine, due to their differentiation 
capacity. Cell differentiation involves a profound rewiring of gene expression and 
metabolism, including a mitochondrial remodeling. Several observations previously made in 
our group support a possible translational regulation, potentially involved in the mitochondrial 
remodeling observed during the hepatogenic differentiation of BM-MSCs. Regulation of the 
eukaryotic Initiation Factor 4E (eIF4E)-Binding Protein (4E-BP1)-eIF4E axis is a major 
regulator of the eIF4F complex assembly, regulating cap-dependent translation initiation. In 
addition, the growth-promoting mTOR complex 1 is known to ensure mitochondria 
biogenesis through the regulation of the eIF4E-4EBP1 axis. 
In this work we show a mTOR-associated regulation of the eIF4E-4EBP1 axis affecting 
4EBP1 phosphorylation and its binding activity to initiation factors leading to formation of 
eIF4F complex in differentiating cells. Unexpectedly, the translational rate in those cells is 
not increased upon hepatogenic induction, as compared with undifferentiated cells, while it is 
slightly increased in the late maturation step of the differentiation protocol. Altogether these 
results led us to hypothesize a possible cap-independent-based translational regulation during 
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Figure 1. Mitochondrial remodeling and metabolic shift upon stem cell differentiation (Lisowski et al., 2018).  Stem cells mitochondria 
show immature features with low OXPHOS activity, immature cristae, a more fragmented morphology of the mitochondrial network and 
perinuclear localization. Upon differentiation, mitochondria undergo remodeling with an increase in their number and OXPHOS activity with 
developed cristae, a more fused network which localization is well spread throughout the cytosol. Stem cells present low levels of ROS (but the 
latter are nonetheless required as signaling molecules). In case of DNA damage, stem cells are highly sensitive to mitochondria-dependent 
apoptosis and show increased expression of pro-apoptotic proteins of the B cell lymphoma 2 (Bcl2) family. Differentiation and oxidative-based 
metabolism trigger increase in endogenous ETC leaking resulting in increased ROS levels, associated with an increased susceptibility to DNA 
damages. Mitochondria in differentiated cells show increased expression of anti-apoptotic proteins, reducing cell-death susceptibility. During 















1. A variety of stem cells are considered for cell therapy 
 
 Differentiation is a wide-spread cellular process in the living world and is necessary for the 
acquisition of complexity and functional organization in pluricellular organisms. The starting point 
of this complex phenomenon relies on a particular set of cells called stem cells. These cells are 
characterized by self-renewal capacity and the ability to differentiate into one or more cell lineages, 
this property being called cell potency (Ullah et al., 2015; Wanet et al., 2015). Different kinds of stem 
cells exist with different potencies and origins: embryonic stem cells (ESCs), found in the blastocyst’s 
inner cell mass, are pluripotent (meaning that they are capable of differentiation toward all cell 
lineages thus giving rise to the three primary germ layers); adult or somatic stem cells (SSCs) found 
in most tissues of adult organisms, are either multipotent (able to differentiate into some cell lineages 
derived from a sole primary germ layer) or unipotent (able to differentiate into only one cell type); 
and, finally, the more recently described induced pluripotent stem cells (iPSCs), correspond to 
somatic differentiated cells reprogrammed into a pluripotent state thanks to the overexpression of 
pluripotency master transcriptional regulators (Takahashi & Yamanaka, 2006; Wanet et al., 2015). 
This latter kind of stem cells shows great promises for cell-based therapy and also for gene therapy 
(reviewed in, Mikkers et al., 2012). Nonetheless, currently, the use of Yamanaka and Takahashi’s 
OKSM cocktail of transcription factors (Oct3/4, Klf2, SOX2 and c-Myc) and iPSCs for medical 
application is still waiting for further validation due to the tumorigenic potential and the incomplete 
understanding of these cells (Ghosh et al., 2011; reviewed in, Tapia & Schö Ler, 2016). 
ESCs have been most deeply described in mouse but recent advances in human ESC (hESC) 
characterization allow for a better understanding of their biology and for the improvement of their in 
vitro culture (Sperber et al., 2015; Theunissen et al., 2014). However, these cells present ethical issues 
associated with their origin, show genomic instability and have tumorigenic potential compared to 
somatic stem cells (Ghosh et al., 2011). Recently, an enhanced type of pluripotent stem cells (PSCs: 
ESCs and iPSCs), called extended pluripotent stem (EPS) cells, have been developed. These cells 
present totipotency, meaning that they can give rise to embryonic and extraembryonic tissues while 
PSCs can only differentiate into embryonic tissues. In addition, EPSs show greater genomic stability 
than PSCs and interspecies chimerism ability which is extremely limited for PSCs (Yang et al., 2017). 
Actually, the other kinds of stem cells and more particularly SSCs represent, so far, a safer and more 
commonly accepted alternative for medical concern.  
 SSCs can be found in most tissues of the human body and although they present limited potency 
(multipotent instead of pluripotent), these stem cells remain attractive for cell-based therapy. Indeed, 
due to their high genomic stability and easy access with less associated ethical issues, this kind of 
stem cells represents a really powerful tool for regenerative medicine and cellular therapy (Iansante 
et al., 2018; Rodrigues et al., 2010; Ullah et al., 2015; Wanet et al., 2015). SSCs gather progenitor 
cells as well as Mesenchymal Stem Cells or Mesenchymal Stromal Cells (MSCs). According to the 
definition proposed by the International Society for Cellular Therapy, Mesenchymal Stromal Cells 
are heterogenous populations of cells found in many tissues and deriving from mesodermal lineage 
with a fibroblast-like phenotype and plastic adherence property (Dominici et al., 2006). Among this 
cell population, the ones presenting specific features such as the expression of specific surface 
markers (CD73, CD90 and CD105) and absence of other ones (CD14, CD34, CD45 and HLA-DR) 
with the ability to differentiate at least into osteoblasts, chondrocytes and adipocytes are called 
Mesenchymal Stem Cells (Horwitz et al., 2005). These stem cells have raised increasing interest for 
medical applications, partly due to their immunomodulatory properties, and represent models of in 
vitro differentiation (Banas et al., 2007; Iansante et al., 2018; Najar et al., 2013; Stock et al., 2014; 
Ullah et al., 2015). Indeed, these cells have the ability to trans-differentiate into ectodermal and 
 
Figure 2. Mitochondria as the gatekeeper of stem cell metabolism through bioenergetic and redox regulation and ensuring metabolic 
regulation of the epigenetic landscape (adapted from Lisowski et al., 2018).  (A) The nutrient sources influence the epigenetic 
landscape of stem cells and favor stemness maintenance. Among the main metabolites involved in epigenetic regulation which are mainly derived 
from glucose or lipids, the acetyl-CoA and citrate can translocate from mitochondria to cytoplasm and give acetyl-CoA thanks to the action of the 
ATP-citrate lyase enzyme. The latter metabolite is a substrate of histone acetyl-transferase (HAT) enzymes that acetylate histones, ensuring an 
open chromatin context which plays a role in PSC maintenance. At the opposite, histone deacetylases (HDACs) promote the removal of the 
acetylated marks and favor thus a more closed and repressive state of the chromatin. Another important metabolite involved in epigenetic regulation 
is α-ketoglutarate which can be derived from glutamate and glutamine through glutaminolysis. Glutamine is a major substrate for stem cells. α-
ketoglutarate is a co-substrate for ten-eleven translocation (TET) methylase generally associated with transcription repression and Jumonji C 
domain demethylase (JHDMs) enzyme promoting either transcription activation or repression. Bioenergetic regulation is also involved in 
epigenetic regulation through AMP-activated protein kinase (AMPK) activation sensitive to the ATP/ADP ratio; AMPK is involved in the 
shutdown of anabolic process and stops proliferation, thus constituting a roadblock in reprogramming and impairing stemness maintenance. The 
reductive state of the cells also plays a role as high NADH/NAD+ ratio, associated with higher Krebs cycle activity, leads to the inactivation of 
sirtuins such as Sirtuin 1, a deacetylase enzyme favoring stem cell maintenance (Lisowski et al., 2018; Rodriguez et al., 2013). Finally, ROS 
signaling is also involved in epigenetic regulation where those reactive species can promote histone methyl transferase (HMT) and DNA methyl 
transferase (DNMT) oxidation and subsequent inactivation combined with direct nucleotide oxidation. In stem cells, hypermethylation of the 
nuclear-encoded mitochondrial polymerase gamma A (POLGA) gene keeps the mtDNA copy number and thus mitochondrial activity at low levels.  
(B) An important metabolite involved in epigenetic crosstalk is pyruvate which is mainly derived from glucose utilization through glycolysis, 
enhanced in stem cells, and which is further converted into lactate to restore NAD+ availability. In stem cells, pyruvate follow a metabolic shunt 
and is predominantly used for fermentation in the cytosol. Therefore, it is less used in mitochondria where pryruvate is normally converted into 
acetyl-CoA through pyruvate dehydrogenase complex (PDC) activity. However, in stem cells, strong hypoxia-induced factor 1 α signaling 
promotes PDC kinase (PDK) expression, whose activity inhibit PDC complex activity. Nonetheless, both pyruvate and PDC can be found in the 





endodermal cell lineages, making them potential candidate for regenerative medicine and for 
transversal studies of differentiation processes (Stock et al., 2014).  
 
2. Pluripotency and differentiation regulation through mitochondria-related metabolic 
shift 
 
 A conserved feature of stem cell differentiation concerns the requirement of a metabolic shift to 
ensure efficient differentiation toward some cell lineages. Indeed, mouse and human ESCs priming 
and differentiation involve mitochondrial maturation and transition from a glycolytic-based 
metabolism to an oxidative one (Sperber et al., 2015; Theunissen et al., 2016). This mitochondrial 
remodeling involves a transition of perinuclear mitochondria with poorly developed cristae and low 
Oxidative Phosphorylation (OXPHOS) activity to an extended mitochondrial network with mature 
cristae and an oxidative phenotype (reviewed in, Rafalski et al., 2012; Wanet et al., 2015) (Figure 1). 
This phenomenon, necessary for ESCs differentiation, is also required during the differentiation of 
MSCs into several lineages such as the osteogenic and adipogenic lineages (reviewed in, Hsu et al., 
2016) as well as for the differentiation of neural progenitors toward mature neurons (Agostini et al., 
2016; Xie & Sheppard, 2018; Zheng et al., 2016). In addition, this metabolic shift and its-associated 
mitochondrial remodeling have also been previously described by our team in a model of hepatogenic 
differentiation of human BM-MSCs (hBM-MSCs). Interestingly, the reverse phenomenon is 
observed during the spontaneous de-differentiation of hepatocytes in vitro with reversal of the 
mitochondrial remodeling (Wanet et al., 2014). Similarly, during the reprogramming of somatic cells 
into iPSCs, a transition of mitochondria from a mature to an immature state is observed (Figure 1). 
This process, involving mitophagy, is called mitochondrial rejuvenation (Hawkins et al., 2016; 
Vazquez-Martin et al., 2016; Wanet et al., 2015; J. Zhang et al., 2012). The observed metabolic shift 
upon cellular differentiation is required for proper and complete differentiation process as the 
impairment of mitochondrial respiration prevents differentiation and favors reprograming and 
stemness maintenance (Wanet et al., 2015). 
However, it seems puzzling that stem cells favor a poor energetic-yield glycolytic phenotype over 
a high ATP-yield oxidative metabolism since these cells need to maintain sufficient proliferation rate 
to ensure their self-renewal and tissue homeostasis. Three main raisons can be proposed to explain 
this unexpected metabolic behavior: first, stem cells grow in vivo in hypoxic niches (<5% O2) and so 
a glycolytic metabolism is adapted to this cellular environment. Hypoxic conditions favor the 
stabilization of the Hypoxia-Inducible Factor 1α (HIF1α), a central regulator of stemness, which 
regulates the expression of numerous metabolic genes, ensuring the glycolytic phenotype of stem 
cells (Lisowski et al., 2018; Rafalski et al., 2012; Wanet et al., 2015). Secondly, limited OXPHOS 
activity allow for a low level of ROS produced endogenously by electron leak of the Electron 
Transport Chain (ETC), therefore reducing ROS-induced DNA damage. Furthermost, stem cells are 
highly susceptible to mitochondria-dependent apoptosis mediated in response to DNA damage. 
Indeed, they have high levels of pro-apoptotic proteins, as these cells must ensure tissue integrity and 
cannot afford genetic alterations accumulation (Lisowski et al., 2018). Finally, the increase in 
glycolysis and decrease of oxidative metabolism allow for the redirecting of metabolic flux toward 
anabolic pathways such as the pentose phosphate pathway, resulting in increased nucleotide 
biosynthesis (Lisowski et al., 2018; Wanet et al., 2015).  
Moreover, mitochondria also ensure metabolic regulation of stem cell maintenance and 
differentiation through additional mechanisms: bioenergetic regulation (ATP and redox state 
regulation of the cell), regulation of ROS production and associated signaling and metabolic-
epigenetic crosstalk thanks to the production of some metabolites such as pyruvate or acetyl-CoA 








Figure 3. Signaling pathways involved in human in vivo liver development (adapted from Gordillo et al., 2015).  (A) Nodal signaling 
generated from epiblast (Ep) cells is necessary and sufficient for mesendoderm (ME) specification. BMP and Wnt signaling are involved in the 
reinforcement of Nodal signaling in the posterior epiblast and this auto-regulatory loop leads to the formation of the primitive streak (corresponding 
to gastrulation at day 12) and of the mesendoderm. High levels of Nodal give rise to definitive endoderm (DE) and is antagonized by BMP and 
FGF signaling, promoting mesoderm (M) formation. (B) Gut tube patterning (day 23-26) is dependent on graded BMP, FGF and Wnt signaling 
on the anterior-posterior axis where high levels of these morphogens, in the posterior region, induce mid- and hindgut precursor (MG-HG) 
formation from which derive intestinal progenitors (I). The absence of BMP, FGF and Wnt signaling at the anterior extremity leads to anterior 
foregut precursors (AFG) formation, responsible for the formation of lungs (L) and thyroid (T) progenitors, whereas low levels of these 
morphogens in the anterior side of the embryo promote the formation of posterior foregut precursors (PFG). (C) The latter will give rise to both 
pancreatic (P) progenitors and hepatoblasts, depending on FGF and BMP signaling. (D) Hepatoblast will then give rise to hepatocytes or 
cholangiocytes, where the balance is determined by the presence of specific morphogens in the microenvironment (glucocorticoids, HGF, OSM, 
Wnt and TNFα for hepatocyte differentiation and TGFβ, Notch, BMP, FGF, Wnt and Hippo signaling for biliary differentiation). The maturation 
of hepatocytes and cholangiocytes then occurs from day 56-58 to the end of the gestation (Gordillo et al., 2015). A comparative transcriptomic 
analysis performed on human PSCs-derived hepatocyte-like cells and rodent fetal hepatocytes revealed a lack of metabolic maturity in hepatocyte-








Altogether, these elements underlie the major importance of mitochondria in stem cells acting as 
a metabolic hub regulating both stemness maintenance and differentiation (Lisowski et al., 2018; 
Wanet et al., 2015). The tight interplay and inter-dependency between mitochondria dynamic and cell 
differentiation, underlined by the mitochondrial remodeling-dependent support of the glycolytic- to 
oxidative-based metabolic shift required for several differentiation processes, such as in the 
hepatogenic differentiation of BM-MSCs, highlights an essential role of mitochondria in stem cells 
homeostasis (Lisowski et al., 2018; Wanet et al., 2014, 2015). 
 
3. Liver development and hepatogenic differentiation 
 
The study of liver development has allowed characterization of several molecular mechanisms 
driving this process, allowing the development and progressive enhancement of in vitro hepatogenic 
differentiation protocol. Due to its major metabolic role in the regulation of glucose and urea 
metabolism and detoxification function, the liver represents one of the most complex organs. Its 
development is therefore extremely well controlled and is based on the combination of several 
signaling pathways (Figure 3) (Banas et al., 2007; Gordillo et al., 2015).  
In the early human embryo, Nodal signaling (a member of the transforming growth factor β 
(TGFβ) family) generated from epiblast cells is involved in mesendoderm specification. The Nodal 
signaling is necessary and sufficient for this specification but bone morphogenic protein (BMP) and 
Wnt signaling pathways are also involved in mesendoderm formation. Indeed, both morphogens, in 
the posterior epiblast, ensure the reinforcement of Nodal signaling and this auto-regulatory loop leads 
to gastrulation with the formation of the primitive streak and of the mesendoderm. However, later on 
BMP and fibroblast growth factor (FGF) signaling antagonize Nodal signaling for the segregation of 
endoderm and mesoderm: in one hand, the expression of the key-endodermic transcription factor 
SOX32 is stimulated thanks to high levels of Nodal in order to give rise to definitive endoderm; in 
the other hand, BMP and FGF activation repress the transcriptional activity of SOX32, resulting in 
mesoderm formation. Endoderm is further divided and patterned in three different parts: foregut, 
midgut and hindgut. This patterning is dependent on graded BMP, FGF and Wnt signaling on the 
anterior-posterior axis where high levels of these morphogens, in the posterior region, induce mid- 
and hindgut formation from which derive intestinal progenitors. The absence of BMP, FGF and Wnt 
signaling at the anterior extremity leads to the formation of anterior foregut precursors, responsible 
for the formation of lungs and thyroid progenitors, whereas low levels of these morphogens in the 
anterior part of the embryo promote the formation of posterior foregut precursors. The latter will give 
rise to both pancreatic and hepatic lineages. The subsequent formation of the liver diverticulum is 
dependent on FGF and BMP signaling (Wnt signaling is necessary for liver specification in zebrafish 
but no demonstration for its dependency in mammals has been made so far), provided by the 
surrounding septum transversum cells. In addition, the presence of endothelial cells in the liver 
diverticulum is required for hepatoblast specification and promotes liver budding with the oncostatin 
M (OSM)-dependent proliferation of hepatoblast and their concomitant migration in the septum 
transversum parenchyma. Hematopoiesis then occurs with the migration of hematopoietic 
progenitors in the liver bud. The bipotential hepatoblasts are poised to differentiate into hepatocytes 
or cholangiocytes, depending on the morphogenic microenvironment where glucocorticoids, 
hepatocyte growth factor (HGF), OSM, Wnt and tumor necrosis factor α (TNFα) promote hepatocyte 
differentiation and maturation whereas TGFβ, Notch, BMP, FGF, Wnt and Hippo signaling favor 
biliary differentiation and maturation. The transcription factor T-box Transcription factor 3 (TBX3) 
helps controling the balance between Prospero homeobox protein 1 (Prox1)-Hepatocyte Nuclear 
Factor 4 α (HNF4α) hepatocyte specification and HNF6-HNF1β-SRY-Box 9 (SOX9) biliary 
specification. Liver development per se is achieved in 60 days in human but mature liver is only 






Figure 4. Metabolic zonation of the liver (adapted from Birchmeier, 2016). Nutrients coming from the intestine are transported to the liver 
through the portal venule and are distributed along the periportal-perivenous axis. Similarly, oxygen-enriched blood supplied from the hepatic 
artery follows the same distribution, and the blood from both origins leave the hepatic lobule through the central vein. Flux of bile, follows the 
opposite direction and leaves the lobule through the periportal system (Birchmeier, 2016). The cellular niche and environment of the hepatocytes 
would be essential for the acquirement of the liver zonation and the emergence of specific metabolic feature. Indeed, the identified mediators of 
Wnt pathway involved in the perivenous zone determination would correspond to Wnt7b and Wnt8b, secreted by hepatocytes and cholangiocytes, 
allowing perivenous-related metabolic activity like increase in glutamine synthesis (through the control of GS expression), citric acid cycle, lipid 
synthesis, and cytochrome P450 (CYP450) 1A2 metabolism capacities. At the opposite, the Wnt inhibitory factor-1 (Wif-1), secreted by 
cholangiocytes, would be involved in the suppression of Wnt signaling in the periportal zone, allowing for the increase in urea synthesis (through 
CPS1 expression), gluconeogenesis, and lipid degradation capacities (Mitani et al., 2017). In addition, the metabolic zonation is also dependent on 
the Frizzled co-activator receptors Leucine Rich Repeat Containing G Protein-Coupled Receptor 4 (LRG4) and 5, involved in Wnt-β-catenin 
activation; the presence of the extracellular ligand R-spondin (RSPO); and of the two E3 ligases: Zinc and Ring Finger 3 (ZNF3) and Ring Finger 
Protein 43 (RNF43). The interaction between Frizzled, LGR4/5 and RSPO is necessary to respond to Wnt signaling. At the opposite, ZNF3 and 
RNF43 provide the degradation of both LGR receptors and thus reduce Wnt signaling. Henceforth, the spatio-temporal control of the metabolic 
zonation would involve the graded expression of both activating and inhibitory signaling (Birchmeier, 2016). In addition, hepatocytes, as well as 
hepatocyte-like cells, show metabolic plasticity as they can rapidly adapt and change their metabolic phenotype following to exposure to perivenous 











A last step in liver development corresponds to the acquirement of a metabolic zonation in the 
liver where hepatocytes located in the perivenous area show distinct metabolic features compared 
with hepatocytes located in the periportal area of hepatic lobules. The metabolic properties of both 
area depend on specific expression of metabolic enzymes as for ammonia detoxification enzymes 
(Birchmeier, 2016; Burke et al., 2018; Mitani et al., 2017). Indeed, CPS1 (Carbamoylphosphate 
synthetase 1) expression, the rate-limiting enzyme involved in urea synthesis, is restricted to 
periportal area whereas the GS (Glutamine synthetase) expression, involved in glutamine synthesis, 
is found in the perivenous area. This specification seems to depend on the Wnt-β-catenin pathway as 
its activation, in the perivenous area, relieves of HNF4-α-dependent repression of GS. The patterned 
activation of this signaling pathway would thus be responsible for the restricted expression of GS and 
CPS1, as the latter is expressed in the absence of Wnt signaling, and would thus be responsible for 
the liver zonation occurring quickly after birth (Figure 4) (Burke et al., 2018).  
Actually, liver diseases leading to hepatic insufficiency represent a major medical issue requiring 
the use of regenerative medicine, where, in some cases, the only solution is liver graft. However, the 
number of graft demands largely exceeds the number of available livers, making hepatic failure 
treatment a currently unresolved issue in our societies. Therefore, alternatives such as cellular therapy 
for regenerative medicine and the use of  in vitro generated hepatocyte-like cells or stem cell-based 
treatments arouse growing interest (reviewed in, Iansante et al., 2018; Terryn et al., 2018). 
 
4. In vitro models of hepatogenic differentiation  
 
The study of liver development and the precise characterization of each step, using initially in vivo 
models, have allowed for the development of in vitro differentiation protocols modelling liver 
development. Further on, those cellular models allow for an even more precise study of the molecular 
events occurring during cell differentiation and liver development and present also therapeutic 
potential (Banas et al., 2007; Gordillo et al., 2015).  
 Several type of stem cells can be used for the generation of hepatocyte-like cells, such as PSCs or 
even multipotent stem cells such as MSCs. In vitro hepatogenic differentiation of PSCs is a common 
model for the study of liver development and hepatocytic differentiation. In this context, a 
comparative analysis of transcriptomic data from PSCs-derived hepatocyte-like cells generated with 
different in vitro protocols and from fetal rodent hepatocytes has been performed. This study showed 
that hepatocyte-like cells transcriptomic profiles were close to murine fetal hepatocyte at embryonic 
day ~E14-15 corresponding to day 48-54 of human gestation (Figure 3), revealing a lack of maturity 
of these hepatocyte-like cells. Interestingly, a genetic roadblock seems to exist during in vitro 
hepatogenic differentiation for all hepatogenic differentiation protocols, leading to early arrest in the 
hepatocytic maturation (Ravali Raju et al., 2018).  
MSCs-based protocols are also used for hepatogenic differentiation where Bone Marrow-derived 
MSCs (BM-MSCs) are considered as the gold standard for MSCs differentiation capacities (reviewed 
in, Ullah et al., 2015). These cells can indeed be trans-differentiated (not differentiated because those 
cells are of mesodermal origin and thus do not naturally differentiate into endodermal lineages such 
as hepatocytes) in hepatocyte-like cells, which represent both a model for the study of processes 
occurring in the early stage of liver development and a potential therapeutic tool (Lysy et al., 2008; 
Wanet et al., 2014). Different protocols of in vitro hepatogenic differentiation exist and involve 
exposure to different cytokine cocktails, mimicking in vivo liver development. Differentiation 
efficiency is commonly assessed by the analysis of hepatocytic-specific markers expression (Albumin 
(ALB), α-fetoprotein (AFP), HNF3β, cytokeratin 18 (CK18), HNF1α, TBX3, HNF4α …) and by 
functional assays recording hepatocytic-specific functions (urea and albumin production, glycogen 




2011; Banas et al., 2007; Najar et al., 2013; Sambathkumar et al., 2018; Saulnier et al., 2009; Snykers 
et al., 2006; Ullah et al., 2015).   
Commonly used differentiation protocols involve sequential exposure of BM-MSCs, grown on 
collagen-coated surfaces, to different cytokine cocktails reflecting in vivo liver development (Banas 
et al., 2007; Najar et al., 2013; Snykers et al., 2006). Generally, hepatogenic differentiation using 
BM-MSCs involves two-step protocol with a first step of differentiation commitment toward 
hepatoblast, involving different factors such as epithelial growth factor (EGF), FGF, HGF) and 
nicotinamide, and a second step of hepatic maturation involving OSM, dexamethasone and insulin-
transferrin-selenium (ITS) (Snykers et al., 2006; Ullah et al., 2015; Wanet et al., 2014). However, 
other differentiation protocols involving the overexpression of liver-specific transcription factors and 
master regulators such as HNF4α, known to regulate liver development and inducing the expression 
of other hepatocytic master regulators like CCAAT-enhancer-binding protein α (C/EBPα) or HNF3β, 
can lead to the acquirement of hepatic functions (enhanced metabolic activity, albumin and urea 
production,…) (Hang et al., 2014). In addition, HNF4α represses the Wnt-β catenin signaling, 
involved in embryo development and osteogenic differentiation, its downregulation being necessary 
for the acquirement of metabolically competent hepatocytes and for liver zonation in vivo (Figure 4) 
(Birchmeier, 2016; Burke et al., 2018; Hang et al., 2014; Mitani et al., 2017). Other differentiation 
protocols using other cell types such as adult liver-derived progenitor cells with sequential 
overexpression of HNF4α and C/EBPα and HNF3β also exist and give functional hepatocyte-like 
cells showing enhanced features for medical application (Iacob et al., 2011). The differentiation 
protocol used in this work has been previously characterized in (Wanet et al., 2014). It involves 
sequential exposure to three different cytokine cocktails comprising all the above-mentioned 
cytokines. The differentiation efficiency has been assessed with the expression of the hepatic markers 
α-1-antitrypsin (α1AT) and Tryptophan 2,3-dioxygenase (TDO2), the developmental marker TBX3 
and the stemness marker SOX9 and functionally assessed using Periodic Acid Schiff (PAS) staining 
(Wanet et al., 2014). In this model, a mitochondrial remodeling has been described, supporting a 
metabolic shift during the hepatogenic differentiation process, highlighting the importance of 
mitochondria in MSCs differentiation (Wanet et al., 2014).  
 
5. Deciphering the molecular mechanisms underlying hepatogenic differentiation   
 
A transcriptomic analysis performed in the early stage of this in vitro hepatogenic differentiation 
program allowed the identification of the tanscription factor 7-like-2 (TCF7L2)-peroxisome 
proliferator-activated receptor gamma (PPARγ) coactivator 1-α (PGC-1α) axis as connecting 
hepatogenic differentiation and mitochondrial remodeling (Wanet et al., 2017). Indeed, PGC-1α is a 
well-known co-activator of numerous transcription factors like PPARγ or the Nuclear Respiratory 
Factors (NRF 1 and 2) involved in the transcription of several nuclear-encoded mitochondrial genes, 
leading to mitochondrial biogenesis and increased OXPHOS activity (Fernandez-Marcos & Auwerx, 
2011; Hsu et al., 2016). In addition, TCF7L2 (also called TCF4) is regulated by the Wnt-β catenin 
pathway which is, according to the transcriptomic analysis,  shown to be downregulated during the 
differentiation, underlining the physiological significance and relevance of this differentiation model 
(Wanet et al., 2017). Interestingly, this analysis also showed modifications in the abundance of 
several translation-related transcripts, suggesting that translational regulation could be an additional 
layer of regulation in the hepatogenic differentiation. Indeed, a KEGG pathway analysis of the 
transcriptomic dataset showed enrichment in ribosome-related genes with upregulation of several 
mitochondria ribosomal genes (Wanet et al., 2017). Some pathways such as the mammalian Target 
of Rapamycin (mTOR) and the eukaryotic Initiation Factor 2 (eIF2) signaling pathways, both 
involved in translation regulation, were also shown to be upregulated during differentiation (Wanet 
























eIF4EBP1 0,53 8,38E-22 0,42 1,44E-61 0,41 5,01E-54 0,29 6,23E-127 
EIF4E 1,64 1,72E-09 1,54 2,45E-10 1,1 1,86E-01 0,96 5,56E-01 
EIF4G1 1 9,49E-01 1,11 3,33E-04 0,92 9,37E-03 0,74 3,61E-24 
EIF4G2 1,13 3,29E-07 1,16 8,66E-14 0,91 8,26E-06 0,89 1,30E-09 
HIF1A 0,87 3,95E-05 0,5 4,80E-175 0,73 2,04E-35 0,48 7,88E-230 
PPARG 3,93 5,88E-14 3,22 1,26E-15 2,76 4,76E-16 3,46 6,69E-22 
KRT7 0,07 5,21E-45 0,06 2,03E-82 0,04 8,75E-67 0,03 9,63E-110 
ATF4 0,34 5,09E-95 0,37 3,36E-109 0,4 1,98E-136 0,49 3,08E-80 
Table 1. Differentially expressed genes encoding translation-related proteins at the early stage of the hepatogenic differentiation process 
of hBM-MSCs. Data extracted from the transcriptomic analysis performed by Wanet et al., 2017.  Cells in expansion, differentiated (diff) and 
undifferentiated (undiff) cells for 3 and 5 days of differentiation, derived from 5 different donors were collected and pooled and total RNA was 
extracted. MACE transcriptomic analysis was then performed on the different samples and data were analyzed for diff condition at days 3 and 5, 
either normalized to undiff or expansion condition.  Data for differential gene expression are expressed in fold changes with their associated p-
value, all the statistical analyses were obtained using the statistical programming language R (www.rproject.org/) with the DEGexp function of 
the DEGseq package (Wanet et al., 2017). Data for some genes of interest linked to translation initiation, major transcriptional regulators and 





1 (4EBP1), a major regulator of translation initiation (detailed hereafter), undergoes a robust 
downregulation in the early stages of the hepatogenic differentiation (Table 1). Likewise, a 
mitochondrial chaperone, mitochondrial heat shock protein 70 (mtHSP70), is slightly downregulated 
at the mRNA level but is upregulated at the protein level during the hBM-MSC hepatogenic 
differentiation, supporting a possible translational regulation (Wanet et al., 2017). Altogether these 
results support the hypothesis of a possible involvement of a translational regulation potentially 
involved in the mitochondrial remodeling observed during the hepatogenic differentiation. 
Although transcriptional and post-transcriptional regulations have been mostly studied, 
translational regulation appears to be as much important and ubiquitous. Indeed, translational 
regulation allows faster adaptation of protein levels than transcriptional regulation and is therefore of 
great importance for the homeostasis maintenance in case of cellular stresses or processes requiring 
rapid protein level modification (Buszczak et al., 2014; Grech & von Lindern, 2012; Holcik & 
Sonenberg, 2005; Sonenberg & Hinnebusch, 2009). But what are the main molecular mechanisms 
underlying translational regulation? Translational regulation can be either global, with the inhibition 
or activation of initiating actors such as the eukaryotic Initiation Factors (eIF, discussed below), 
leading to global protein synthesis repression or enhancement respectively, or it can be specific to 
some mRNAs. In the latter case, it refers to a specific loading of ribosomes on these mRNAs and 
results in an enrichment of these mRNAs in polysome-associated fractions (Hinnebusch et al., 2016; 
Sonenberg & Hinnebusch, 2009). It is commonly accepted that the number of ribosomes loaded on a 
transcript is proportional to the intensity of its translation and thus to the level of corresponding 
proteins. According to this model, it is therefore the regulation of the initiation step of translation that 
constitutes the main mechanism of translational regulation. Different mechanisms underlie the 
translational regulation of specific transcripts, such as non-coding RNA, trans-acting RNA-binding 
Proteins (RBP) or the presence of cis-acting elements in the mRNA sequence itself such as Internal 
Ribosome Entry Sites (IRES) sequences, ensuring cap-independent translation (reviewed in, Holcik 
& Sonenberg, 2005; Komar & Hatzoglou, 2011; Sonenberg & Hinnebusch, 2009; Xue & Barna, 
2012), or upstream Open Reading Frame (uORF) (Hinnebusch et al., 2016; Jackson et al., 2010; King 
& Gerber, 2016; Xue & Barna, 2012). Different molecular complexes and actors are involved in this 
ribosome selectivity for specific mRNAs that concerns mainly cap-dependent translation actors and 
more precisely translation initiation-related ones (Sonenberg & Hinnebusch, 2009).  
Interestingly, several examples of translational regulation have been described in differentiation 
contexts such as hBM-MSC (Spangenberg et al., 2013) and murine 3T3-L1 cell line (Fromm-
Dornieden et al., 2012) adipogenic differentiation and in the hepatogenic differentiation of HepaRG 
cells, an hepatic progenitor cell line (Parent et al., 2007; Parent & Beretta, 2008). In addition, neural 
differentiation in a model of mouse Neural Progenitor Cells (NPCs) and in the Neuro-2a murine cell 
line can be achieved by chemically-induced translational upregulation of specific neural transcription 
factors (Liao et al., 2018). Altogether, this supports the possibility of a translational regulation 
involved in our model of hepatogenic differentiation. 
 
6. Coordination between the nucleus and mitochondria involves translational regulation 
 
Mitochondrial genome encodes 13 proteins of the respiratory chain, 22 tRNAs and 2 rRNAs 
whereas nucleus-encoded mitochondrial genes account for more than 1000 proteins (reviewed in, 
Taanman, 1999). Coordination between the two genomes is therefore necessary for mitochondrial 
homeostasis and especially for proper OXPHOS function, as respiratory complexes are of dual origin, 
except for complex II (Formosa & Ryan, 2018). Therefore, genome expression synchronization must 
be tightly regulated and is of even greater importance in contexts of mitochondrial biogenesis and 
remodeling as observed in yeast upon nutrient source transition (Couvillion et al., 2016; Formosa & 




non-fermentable source, like glycerol, requires mitochondrial biogenesis and remodeling to support 
an oxidative shift. In this case, it has been demonstrated that the coordinated assembly of respiratory 
complexes requiring synchronization between the mitochondrial and nuclear genome expression is 
achieved through translation and not transcription. Indeed, upon the nutritive stress induction, the 
transcript levels of mitochondria- and nuclear-encoded proteins of the same respiratory chain 
complex do not show synchronization whereas the translational rate of these transcripts are 
synchronized. An unidirectional communication from cytosolic to mitochondria ribosomes seems to 
ensure this synchronization. For instance, nuclear-encoded mitochondrial translational activators 
such as Cbp6 and Cbs2 are upregulated at the translational level and thus ensure translational 
regulation and enhancement of mitochondria-encoded respiratory chain proteins (Couvillion et al., 
2016).   
  In addition, modifications in ribosome composition and stoichiometry of ribosomal proteins is also 
involved in the regulation of translation upon nutrient source transition, both in yeast and in ESC. 
Indeed, following nutrient source transition, ESC ribosome composition in polysomal and 
monosomomal fractions is modified: the ribosomal proteins Rps14 and 29 are enriched in polysomes 
and Rpl11 is enriched in monosomes, suggesting a mechanism of translational regulation associated 
with the metabolic shift and mitochondrial remodeling. Modification of ribosomal proteins 
stoichiometry can also lead to ribosome imbalance and the freeing of ribosomal proteins which can 
ensure other functions. Indeed, extra-ribosomal functions have been described as in a case of 
ribosomal biogenesis defect where the sequestration of mouse double minute 2 (Mdm 2), the E3-
ubiquitin ligase involved in the tumor suppressor p53 degradation, by free ribosomal proteins as (Rpl5 
and Rpl11), results in p53 stabilization and increased activity. This phenomenon is also observed in 
case of proteotoxic stress where ribosomes stalling following an unfolded protein response 
contributes to p53 stabilization by free ribosomal proteins. Therefore, translational regulation, 
through ribosomal protein stoichiometry regulation at least, occurring in stem cell favors tissue 
homeostasis and prevents oncogenic transformation (reviewed in, Buszczak et al., 2014).   
 Paralog selectivity would also be involved in translational regulation and contribute to the 
coordination between mitochondria and the nucleus following external stimuli (Segev & Gerst, 2018; 
Xue & Barna, 2012). Indeed, in yeast, upon nutrient source transition, the ribosomal protein Rpl1b is 
mainly expressed over its paralog Rpl1a leading to the specific translation of mitochondrial transcripts 
involved in major mitochondrial pathways. The subset selectivity would depend on the presence of 
specific 3’UTR in the concerned mRNAs (Segev & Gerst, 2018). Moreover, ribosomal genes 
paralogues show tissue-specific expression in mammals and, in yeast, ~70% of all ribosomal 
paralogues protein are asymmetrically expressed (Xue & Barna, 2012).   
  Post-translational modifications of ribosomal proteins also lead to the specific regulation of mRNA 
translation as for Rpl13 phosphorylation, which triggers its dissociation from the 60S subunit leading 
to translational repression of the Ceruloplasmin transcript (Grech & von Lindern, 2012; Kapasi et al., 
2007; Sonenberg & Hinnebusch, 2009). In yeast, the polyubiquitination of Rpl28 leads to an increase 
in ribosome activity, highlighting the role of post-translational modifications of ribosomal proteins in 
the control of translation, also found in human where at least 11 proteins of the large subunit and 
almost all of the small ribosomal subunit undergo post-translational modifications (Xue & Barna, 
2012).    
 Additionally, some ribosomal proteins have been shown to be essential for ESC differentiation, 
potentially through translational regulation. Indeed, a genetic hemizygous loss of exit-site (site of 
tRNA dissociation from the ribosome occurring cyclically during translation elongation) located 
ribosomal proteins Rps5, Rps14 and Rps28 lead to impairment of ESC differentiation in embryoid 
bodies. Interestingly, Rps5 specifically interacts and favors the loading of ribosomes on two 
mitochondria-processing machinery-related ncRNA: RNA component of mitochondrial RNA 
processing (Rmrp) and ribonuclease P RNA component H1 (Rpph1), supporting a positive 
translational regulatory role of some ribosomal proteins for mitochondrial transcripts during the 




Figure 5. Mechanism of cap-dependent translation initiation (Jackson et al., 2010). After recycling from Post-termination complexes (Post-
TC), 40S ribosome associates with the eIF3 complex and with the eIF2 ternary complex, allowing 43S PIC formation. After mRNA activation and 
unwinding, the eIF4F complex associates with the 43S Pre-Initiation Complex (PIC) leading to mRNA binding and to 48S PIC formation. 
Following start codon recognition after 5’ to 3’ scanning, eIF5-dependent GTP hydrolysis leads to ribosomal subunits joining and initiation factors 
displacement. The terminal hydrolysis of GTP by eIF5B allows eIF1A release from the functional 80S ribosomal which then goess to the elongation 
and termination step. At the end of the process, ribosomal subunits, releasing factors and PABP are recycled and available for another round of 






stem cell allows for the control of their differentiation and adds another layer of tight control ensuring 
organism development and tissue homeostasis.  
Protein synthesis has been further shown to be mainly regulated during different differentiation 
processes while protein degradation seems constant, in agreement with energy sparing (Kristensen et 
al., 2013). Indeed, in ESC, protein synthesis rate is maintained low despite their actively dividing 
state and a global increase in protein synthesis is required for their differentiation (Buszczak et al., 
2014; Sampath et al., 2008). However, in those cells, protein degradation is required for the 
maintenance of pluripotency while reduced proteasomal activity support the differentiation process. 
Thus, translational regulation during differentiation is obviously a process of major importance and, 
indeed, all the transcriptional and epigenetic rewiring observed during differentiation are ultimately 
and functionally regulated at the translational level (Buszczak et al., 2014). 
 
7. Canonical translation initiation and the eIF4E-4EBP1 axis 
 
Protein synthesis can thus be initiated through cap-dependent or independent translation of mRNA, 
the latter process involving IRES, which are specific sequences found in many mRNAs. IRES-
dependent translation of mRNAs has been first described in case of viral infection where global 
protein synthesis, and so cap-dependent translation, is repressed, allowing for the translation of 
specific mRNAs. The IRES sequences are complex secondary structures contained in mRNAs which 
interact directly with the ribosomal 40S subunit without initiation factors and so avoid the scanning 
required for cap-dependent translation (Holcik & Sonenberg, 2005; Komar & Hatzoglou, 2011; 
Sonenberg & Hinnebusch, 2009). This type of translation is less competitive for polysome 
recruitment than classical cap-dependent translation and represents a first layer of translational 
regulation because of the preferential translation of specific mRNAs. This kind of translational 
regulation has been described in differentiation processes. Indeed, in megakaryocyte differentiation, 
the preferential translation of Platelet Derived Growth Factor 2 (PDGF2) transcript is involved in 
the differentiation process, and is dependent on the IRES trans-acting factor (ITAF) heterogeneous 
nuclear ribonucleoprotein C (hnRNP C) which recognizes the IRES sequence and enhances ribosome 
binding on this transcript (Grech & von Lindern, 2012). 
Nonetheless, cap-dependent translation is the main and canonical mechanism of translation and 
takes place in four steps -initiation, elongation, termination and ribosome recycling- involving 
eukaryotic initiation factors (eIF), elongation factors (eEF) and releasing factors (eRF) (Figure 5) 
(Dever & Green, 2012; Jackson et al., 2010). 
 
a) Canonical translation initiation 
 
 Translation initiation occurs in several steps and involves many actors. In a first step, 40S 
ribosomal subunits recycled from Post-termination complexes (Post-TC) (80S complexes following 
the termination step) are bound by eIF1, eIF1A and eIF3 leading to the subsequent recruitment of the 
eIF2-GTP-Met-tRNAi ternary complex and of eIF5 (the GTPase-Activating Protein (GAP) of eIF2), 
resulting in the 43S Pre-Initiation Complex (PIC) formation. Simultaneously, eIF4E binds the 
scaffold protein eIF4G and forms, together with eIF4A (the GTP-dependent mRNA helicase), the 
eIF4F complex. The eIF4F complex will then connect the mRNA with 43S PIC thanks to 
simultaneous binding of eIF4G to eIF3 and recognition of mRNA m7GTP cap by eIF4E. eIF4G also 
recruits eIF4B (an RBP, enhancer of eIF4A activity) and Poly-A Binding Protein (PABP) (a protein 
that binds mRNAs 3’UTR poly A sequence). Altogether, these events lead to the 48S PIC formation 
(constituted of 43S PIC, eIF4F complex and an mRNA in closed loop conformation) which is ready 







Figure 6. eIF2α-dependent regulation of translation initiation (Holcik & Sonenberg, 2005). The stress-induced phosphorylation of the α 
subunit of eIF2, by four different kinases activated upon either UV or nutrient stress (GCN2), viral infection (PKR), heme deficiency (HRI) or 












by eIF4A and conformational modification of 40S ribosomal subunit to a scanning-competent open 
conformation triggered by eIF1 and eIF1A coordinated activity. For stable codon-anticodon base-
pairing, the displacement of eIF1 to the P-site is required whereas the binding of eIF1A is reinforced, 
allowing for a closed conformation of 40S ribosomal subunit. Upon recognition of the initiator codon, 
eIF5 induces the hydrolysis of eIF2-bound GTP, leading to a decreased affinity for the 40S subunit 
and thus to its partial release from the 48S PIC. In the final step, eIF5B binding to both 40S and 60S 
ribosomal subunits induces the displacement of all the initiation factors, except eIF1A, from the 40S 
subunit and allows 60S subunit recruitment, resulting in the 80S ribosomal complex formation. The 
hydrolysis of eIF5B-bound GTP leads to its dissociation and eIF1A dissociation from the newly 
formed 80S ribosomal complex, now functionally operational for translation elongation and then 
termination. Translation is a cycling process where all factors are recycled at the end of their 
corresponding step excepted PABP, which remains associated with the poly(A) tail of mRNA all 
along the translation process. PABP interacts with eRF3 during termination and would facilitate the 
recycling of 40S subunits from Post-TC (Figure 5) (Jackson et al., 2010). 
The initiation step, described as the most regulated one (Caron et al., 2004; Holcik & Sonenberg, 
2005; Richter & Sonenberg, 2005), is mainly regulated at the level of eIF2 and of the eIF4F complex 
formation (Holcik & Sonenberg, 2005; Mader et al., 1995; Qin et al., 2016; Sonenberg & Hinnebusch, 
2009).   
 eIF2 is a small G protein needed for the recruitment of the initiator-tRNA (Met-tRNAi) and for its 
association with the 40S subunit. In case of different cellular stresses such as viral infection, heat 
shock, osmotic shock, unfolded protein, or heme deficiency, the α-subunit of eIF2 is phosphorylated, 
thereby decreasing its interaction with eIF2B, the Guanosine Exchange Factor (GEF) of eIF2, which 
is necessary for eIF2 activity (Figure 6). eIF2α phosphorylation thus resulting in global protein 
synthesis repression. The kinases targeting the α-subunit phosphorylation of eIF2 correspond to at 
least four different kinases: Protein Kinase RNA-activated (PKR), PKR-like Endoplasmic Reticulum 
Kinase (PERK), Heme Regulated Inhibitor (HRI) and General Control Nonderepressible 2 (GCN2)) 
(reviewed in, Holcik & Sonenberg, 2005). The subsequent shutdown of cap-dependent translation 
allows cell adaptation through, for example, cap-independent translation of specific transcripts such 
as IRES-containing one in case of viral infection. 
Another mechanism of cap-dependent translation initiation regulation involves the regulation of 
the eIF4F complex formation, responsible for the assembly of the mRNA with the 43S PIC leading 
to 48S PIC formation (Figure 5). The assembly of the complex is ensured by the cap-binding protein 
eIF4E which binds m7GTP of all capped mRNA and recruits the scaffold protein eIF4G (Jackson et 
al., 2010; Sonenberg & Hinnebusch, 2009). Structurally, eIF4E is a glove-shaped protein composed 
of 8 anti-parallel β-strands and 3 α-helixes. The cavity formed by the 8 β-strands corresponds to the 
cap binding site, while the 3 α-helixes located on the dorsal surface of the protein act as a binding 
domain for regulatory proteins and for eIF4G binding. eIF4E binds the conserved YXXXXLΦ eIF4E 
binding motif (where X is any residue and Φ any hydrophobic residue) on eIF4G and this binding has 
a positive allosteric effect to increase eIF4E affinity for the cap (Mader et al., 1995; Siddiqui et al., 
2012). This involves a conformational modification of the eIF4E-cap complex which propagates from 
the dorsal binding site to the cap-binding site (Siddiqui et al., 2012). eIF4G will then recruit the other 
components of the eIF4F complex: the helicase eIF4A, responsible for the unwinding of mRNA 
secondary structures, and its activator eIF4B and PABP, allowing the circularization of the mRNA 
associated with translation (Jackson et al., 2010). Additionally, several actors of this complex are 
specifically regulated by post-translational modifications, isoform-specific expression and/or by 






b) Regulation of eIF4F complex by post-translational modifications 
 
A first example involves eIF4G phosphorylation, associated with the translation of specific 
mRNAs during the cell cycle where the translation is globally reduced to 75-80%, underlining 
translational regulation of common cellular processes (Dobrikov et al., 2014). eIF4E is also 
phosphorylated on two different residues: Ser53 and Ser209 (Hinnebusch et al., 2016; Jackson et al., 
2010; Koromilas et al., 1992; C. Schmidt et al., 2016). The first phosphorylation is associated with 
an interesting feature of eIF4E which concerns its stronger affinity for specific mRNAs such as 
ornithine decarboxylase (ODC) or Myc mRNAs, leading to their specific translation (Culjkovic et al., 
2006, 2007; Osborne & Borden, 2015). This eIF4E-translational specificity for some mRNAs seems 
dependent of the structure and complexity of 5’UTR. Indeed, mRNAs bearing abundant secondary 
structures are more sensitive to eIF4E translational activity and this feature would require the Ser53 
phosphorylation of eIF4E as a S53A mutant shows decreased translation of these specific mRNAs 
(Hinnebusch et al., 2016; Koromilas et al., 1992).  
  Although controversial, eIF4E Ser209 phosphorylation is generally associated with increased 
translation (Jackson et al., 2010; C. Schmidt et al., 2016). This phosphorylation is achieved by 
mitogen activated protein kinase (MAPK) interacting kinase 1 (MNK1) and MNK2, two kinases 
associated with the eIF4F complex through their binding with eIF4G (Jackson et al., 2010). 
Nonetheless, Ser209 phosphorylation seems necessary for the sumoylation of eIF4E by the small 
ubiquitin-like modifier (SUMO)-conjugating enzyme UBC9, which results in eIF4E translational 
activity enhancement. Indeed, SUMO-1 conjugation to eIF4E would result in an increase in eIF4G 
association and decrease binding of its inhibitory protein eIF4E-binding protein 1 (4EBP1), whose 
function is detailed hereafter. Altogether this would ensure the pro-oncogenic and anti-apoptotic 
function of eIF4E due to increased translation of growth-promoting and anti-apoptotic transcripts 
harboring a complex 5'UTR (Xu et al., 2010). 
 
c) Regulation of eIF4F complex by isoform specificity 
 
Another layer of eIF4F complex regulation corresponds to the presence of different isoforms of 
eIF4E. Indeed, several isoforms of eIF4E exist with tissue-specific expression, eIF4E1 being the main 
isoform reported to be ubiquitous (Kubacka et al., 2015). This isoform, is present in two others 
isoforms, presenting opposite functions: eIF4E1a and b. These isoforms provide an example of 
isoform-specific regulation of translation initiation. The first of these two isoforms is the 
translationally active form and canonical isoform, whereas eIF4E1b would act as a translational 
repressor thanks to its association with eIF4E-Transporter (4E-T) and the cytoplasmic 
polyadenylation element-binding protein (CPEB) mRNP repressor complex, known to bind the 
3’UTR of specific mRNAs (Kubacka et al., 2015; Richter, 2007). The association of eIF4E1b with 
the CPEB complex and 4E-T would lead to the formation of a “closed-loop” structure with the 
concerned mRNAs leading to their translational repression (Jackson et al., 2010; Minshall et al., 2007; 
Sonenberg & Hinnebusch, 2009).   
 
d) Regulation of eIF4F complex by interacting proteins and eIF4E-4EBP1 axis 
 
Finally, the formation of eIF4F complex is mainly modulated at the level of eIF4E as different 
families of negative regulators recognize and bind the initiation factor, preventing its association with 
eIF4G and thus eIF4F complex assembly, leading to global protein synthesis repression. Four 
different families of negative regulators can be described: (i) the RING domain-containing family 
with the Promyelocytic Leukemia protein (PML), (ii) HHARI and the arenavirus Z protein, using 
their RING domain for eIF4E binding and inhibition, associated with a 100 fold decrease in eIF4E 










Figure 7. Phosphorylation-dependent control of 4EBP1 stability through ubiquitin-dependent proteasomal degradation (Yanagiya et al., 
2012).  The phosphorylation status of 4EBP1 influences its stability as the hypophosphorylated eIF4E-bound 4EBP1 and hyperphosphorylated 
unbound forms are more stable than the hypophosphorylated unbound 4EBP1. The KLHL25-CUL3 complex presents higher affinity for 
hypophosphorylated 4EBP1 and targets the unbound hypophosphorylated form of 4EBP1 to the ubiquitin-dependent proteasomal degradation. 















Homeodomain Protein (PRH), Hox11, HoxA9, bicoid, Engrailed-2 (EN2) and Empty Spiracles 
Homeobox 2 (EMX2), which bind eIF4E using the same conserved site than eIF4G; and (iv) VpG 
proteins, that use amphipathic helix strategy to form a ternary complex with eIF4E and eIF4G 
(Osborne & Borden, 2015). However, among the regulatory proteins, the most important family 
remains the fourth one which corresponds to the eIF4E-binding proteins or 4EBPs, composed of three 
members in mammals: 4EBP1, the most studied and abundant isoform, 4EBP2, which shows similar 
properties than 4EBP1, and 4EBP3, a shortened isoform with distinct features. Those regulators share 
with eIF4G the conserved eIF4E binding motif and enhance eIF4E cap affinity. However, they 
prevent eIF4G recruitment since they bind the dorsal surface of eIF4E on the same site than eIF4G, 
which results in the inhibition of eIF4F complex formation and translation initiation (Mader et al., 
1995; Richter & Sonenberg, 2005). Interestingly, 4EBP1 expression is shown to be downregulated in 
the early steps of the hepatogenic differentiation of BM-MSCs, supporting a potential role of a 
translational regulation during this process (Table 1). 
An example of translational regulation involving the eIF4E-4EBP1 axis concerns the transcription 
factor Yin-Yang 2 (YY2), whose translation is specifically enhanced by eIF4E which shows enhanced 
affinity for the transcript. This transcription factor promotes the transcription of nuclear-encoded 
mitochondrial genes such as mitochondrial ribosomal genes and is involved in stemness regulation. 
Indeed, YY2 is a negative regulator of pluripotency markers such as Myc or Oct4. The enhanced 
affinity of eIF4E for YY2 transcript is regulated by alternative splicing: the RBP polypyrimidine tract 
binding protein 1 (PTBP1) protects YY2 mRNA against splicing, leading to intron retention and thus 
resulting in a transcript with a longer 5'UTR. Such long 5’UTR transcript is more sensitive to eIF4E 
specific translational activity and thus to 4EBP1 or 2 repression. Therefore, the loss of 4EBPs by 
double knock-out (DKO) performed in mouse ESCs, favors mesodermal differentiation with cardiac 
lineage specification thanks to the increased level of YY2 and subsequent downregulation of 
pluripotency markers (Tahmasebi et al., 2016). Thus, reduced abundance of 4EBPs favors 
differentiation, thanks to the increased abundance of YY2. 
 The eIF4E-4EBP1 complex is further regulated by phosphorylation of 4EBP1, leading to its 
dissociation from eIF4E due to conformational changes. Moreover, 4EBP1 phosphorylation seems to 
be hierarchical and involves multiple sites phosphorylation. The canonical model for 4EBP1 
phosphorylation involves the successive phosphorylation of T37 and T46 required for T70 
phosphorylation which would lead to 4EBP1 dissociation from eIF4E (Gingras et al., 2001). 
However, as 4EBPs-eIF4E complexes have been detected even after T70 phosphorylation, it suggests 
that other post-translational modifications are needed (Gingras et al., 2001; X. Wang et al., 2003). It 
seems that a fourth successive phosphorylation on S65 is necessary (Gingras et al., 2001) for eIF4E 
release, both with constitutive and remote phosphorylation upon S101 and S112, potentiating the p-
S65 effect over 4EBP1 loss of binding activity (X. Wang et al., 2003). One of the main signaling 
pathway involved in 4EBP1 phosphorylation on T37/46, and which will be discussed hereafter, is the 
mTOR pathway and more precisely the mTOR Complex 1 (mTORC1), sensing amino acid 
availability (Morita et al., 2013; Schalm et al., 2003; Showkat et al., 2014). However mTORC1 is not 
the only kinase responsible for 4EBPs phosphorylation as other kinases could also act as negative 
regulators for 4EBP binding activity, such as dual specificity tyrosine phosphorylation regulated 
kinase 2 (DYRK2), extracellular signal-regulated kinases (ERK), AKT or other downstream actors 
of mitogen or insulin signaling pathways (Esnault et al., 2017; Qin et al., 2016; X. Wang et al., 2003). 
   
 Another important feature of 4EBP1 regulation is the protein stability and its ubiquitin-dependent 
degradation. Indeed, the unphosphorylated 4EBP1 free form is endogenously ubiquitinated and thus 
targeted for degradation by the proteasome, a process influenced by the phosphorylation status of 
4EBP1. Indeed, the specific E3 ligase of 4EBP1 would be the KLHL25-CUL3 complex which would 





Figure 8. mTORC1 and 2 composition, cellular functions and regulation (adapted from, Proud, 2007; Showkat et al., 2014).  (A) 
The mTORC1 and 2 complexes involve different actors and target different proteins for their phosphorylation but also differ in their sensitivity to 
rapamycin (an inhibitor of mTORC1 but not mTORC2) and upstream signals (reviewed in, Showkat et al., 2014; Roux & Topisirovic, 2012). The 
mTORC1 complex is composed of the adaptor protein Raptor (Regulatory associated protein of mTOR), mLST8 (also called G-protein-β-subunit-
like protein, GβL), PRAS40 (proline-rich AKT/PKB substrate 40kDA), and Deptor (death domain containing mTOR interacting protein). 
mTORC1 mainly stimulates mRNA translation and other anabolic pathways in response to environmental stimuli such as hormonal or nutritive 
ones (Morita et al., 2013; Showkat et al., 2014). Concerning mTORC2, it is composed of the adaptor protein Rictor (Rapamycin-insensitive 
companion of mTOR), mSin1 (mammalian stress-activated protein kinase (SAPK) interacting protein 1), Protor (protein observed with Rictor), 
mLST8, Deptor, and PRAS40 and this complex is involved in the phosphorylation of AKT, itself involved in the activation of both mTOR 
complexes (Showkat et al., 2014). mTORC2 can also activate other kinases of the protein kinase A, G, and C families (AGC kinases) and is thus 
involved in the control of cell survival, cytoskeleton organization, lipogenesis, and gluconeogenesis (Morita et al., 2013; Showkat et al., 2014). 
(B) Activation of mTORC1 following the phosphorylation-dependent inhibition of TSC1-TSC2 complex acting as the GTPase negatively 
regulating Rheb, the small protein activator of mTOR found in mTORC1.Among the positive regulators of mTOR activity are found AKT, ERK, 
AMPK and GSK3. Interestingly a cross-talk exists between mTORC1 and mTORC2 as the latter one activates AKT, a positive regulator of 
mTORC1 activity. mTORC1 phosphorylates two main targets: 4EBP1 and S6K1 through the recognition of their TOR signaling motif (TOS) and 
thus enhances translation. In addition, mTORC1 promotes the translation of a specific pool of transcripts containing 5’Terminal OligoPyrimidine 





8. mTOR regulation of eIF4E-4EBP1 axis  
 
 mTOR is a conserved Ser/Thr kinase of the Phosphatidyl-3-phosphate Kinase (PI3K) family which 
can be found in association with different proteins therefore forming two different complexes (see 
detail in Figure 8A). The activation of mTOR is ensured by a small G protein, Ras homologue 
enriched in brain (Rheb) which activity is inhibited by the complex formed of Tuberous Sclerosis 
Complex 1 (TSC1)-TSC2 acting as its GTPase-Activating Protein (GAP). The phosphorylation of 
TSC2 on several residues by AKT results in the dissociation of the inhibitory complex and thus in 
mTOR activation (Figure 8B) (Inoki et al., 2002; Proud, 2007; Showkat et al., 2014). Indeed, TSC2 
and TSC1 are bound to the lysosomal membrane where they interact together as well as with Rheb. 
Upon AKT-dependent phosphorylation, TSC2 is bound and sequestrated by 14-3-3 protein in the 
cytosol leading to the destabilization of the TSC1-TSC2 complex (Cai et al., 2006; Inoki et al., 2002). 
However, regulated in development and DNA damage responses 1 (REDD1, also known as DNA 
damage inducible transcript 4 or DDIT4), a negative regulator of mTOR signaling pathway compete 
with TSC2 to bind 14-3-3 protein. Upon release, TSC2 is free to interact with TSC1, leading to Rheb 
inhibition resulting in mTOR inhibition independently of AKT activation or TSC2 phosphorylation 
(DeYoung et al., 2008).  
 The canonical and main targets of mTORC1 are the 4EBP1 and 2 and the ribosomal protein S6 
(RPS6) kinase 1 (S6K1) which phosphorylation induces the repression and activation of their activity 
respectively. Upon phosphorylation, 4EBP1 and 2 isoforms lose their affinity for eIF4E making 
eIF4E available for eIF4F complex formation, thereby resulting in translation initiation (Magnuson 
et al., 2012; Schalm et al., 2003; Showkat et al., 2014). The phosphorylation of S6K1 promotes its 
activity, leading to the phosphorylation of its numerous targets, the main one being RPS6. RPS6 
phosphorylation is necessary for the 80S ribosomal complex assembly, therefore supporting a role 
for the mTORC1-S6K1 axis in cell growth (reviewed in, Magnuson et al., 2012).   
 In addition, mTOR and principally mTORC1 complex specifically promotes the translation of 
nuclear-encoded mitochondrial proteins, especially proteins of the ATP synthase (complex V). 
mTORC1 also promotes mitochondrial biogenesis as shown by a decrease in mtDNA abundance and 
respiratory capacity following Raptor depletion or mTOR inhibition. This specific regulation of 
mTOR translational activity is achieved through 4EBP1 phosphorylation as its depletion reduces the 
negative effects of mTOR inhibition on mitochondrial function following inhibitory treatment of 
mTOR (Morita et al., 2013). In addition, mTORC1 also regulates mitochondrial biogenesis through 
transcriptional mechanisms and has indeed been described to be involved in the direct transcriptional 
regulation of estrogen-related receptor α (ERRα) target genes involved in metabolic processes related 
to mitochondria, such as gene encoding proteins of the tricarboxylic acid cycle or involved in 
lipogenesis (Morita et al., 2015). Moreover, mTORC1 is known to control mitochondria respiratory 
capacity through the YY1- PGC-1α axis. The transcription factor YY1 is a known regulator of 
mitochondrial respiration through its inducible action on several mitochondrial genes and on PGC1α 
and acts in coordination with PGC1α itself. The association between the two transcriptional regulators 
requires mTORC1 activity, while rapamycin treatment disrupts their association and provokes a 
downregulation of the mitochondrial target genes (Cunningham et al., 2007). In a PTEN-/- 
(Phosphatase and tensin homolog) model of mouse embryonic fibroblast (MEF), an increase in 
mitochondria activity is observed, supporting the role of mTORC1 in the promotion of mitochondrial 
biogenesis through the eIF4E-4EBP1 axis regulation. Indeed, the consequent upregulation of the 
PI3K-AKT pathway leads to increased mTORC1-containing mTOR activity and thus to the 
phosphorylation of 4EBP1, whose expression is additionally decreased, leading to an increase in 
translation of transcripts encoding mitochondrial proteins (Goo et al., 2012). Altogether, mTORC1 
represent a major actor in the control of mitochondria biogenesis and metabolic and respiratory 
activity since the complex coordinates the transcription, through the control of mitochondria-related 









Figure 9. Two models for LARP1-dependent recognition and enhancement of TOP-containing mRNAs (adapted from, Fonseca et al., 
2015; Tcherkezian et al., 2014).  (A) The first model of LARP1-dependent TOP-mRNA specific translation through mTORC1 recruitment 
proposes that LARP1 would recognize and bind the TOP motifs in the target mRNAs and recruit mTORC1 which would spatially relieve the 
4EBP1-dependent inhibition of eIF4F complex assembly through phosphorylation of the surrounding 4EBP1 (Hong et al., 2017; Tcherkezian et 
al., 2014). (B) Further studies suggested an inhibitory role of LARP1 on the TOP mRNA: LARP1 would bind both the 3’and 5’UTR of these 
mRNAs leading to an inhibitory closed-loop conformation. Upon mTORC1 phosphorylation, LARP1 would dissociate from the 5’UTR, leading 













mitochondrial genes (reviewed in, Morita et al., 2015). mTORC1 represents thus an interesting 
candidate linking translational regulation with mitochondrial remodeling. 
Interestingly, mTORC1 has been shown to play a capital role in adipogenesis in MEFs and in the 
adipogenic differentiation of the murine 3T3-L1 cell line through induction of PPARγ (Magnuson et 
al., 2012; H. H. Zhang et al., 2009). In mouse, mTOR-dependent S6K1 activation participates to the 
commitment stage of adipogenic differentiation, while 4EBP1 and 2 are more specifically involved 
in the terminal differentiation of adipocytes. Indeed, 4EBP1 and 2 DKO mice show increased 
adipogenesis while S6K1 KO mouse shows impaired adipogenesis as for the triple KO mouse, 
suggesting that S6K1 acts earlier than 4EBPs in the adipogenesis process (Carnevalli et al., 2010). 
4EBP1 and 2 are thus mainly regulated by mTORC1-dependent phosphorylation, contrary to the 
third 4EBP isoform which escapes all negative regulations described so far. Indeed, these mTORC1-
mediated phosphorylation depend on the presence of two conserved motifs: a TOR signaling (TOS) 
motif and a RAIP (referring the amino acid sequence) motif, that are not found in 4EBP3 sequence 
(Chen et al., 2012). The TOS motif, also found in other mTORC1 targets such as S6K1 (Figure 8B) 
(Proud, 2007; Schalm & Blenis, 2002), allows for the binding of Raptor (Schalm et al., 2003; X. 
Wang et al., 2003) whereas the RAIP motif is also involved in Raptor binding and together with the 
TOS motif, allows the mTOR-dependent multiple-site phosphorylation of 4EBP1, in response to 
insulin (V. H. Y. Lee et al., 2008). mTORC1 is also involved in the preferential translation of 
5’Terminal OligoPyrimidine (5’TOP) motif-containing mRNAs, in which the cap moiety is followed 
by a cytosine followed by 4-15 consecutives pyrimidines (Gandin et al., 2016; Masvidal et al., 2017). 
This mTORC1-specific binding to TOP-containing mRNAs leads to the specific translation of these 
mRNAs (mainly mRNA encoding translation-related proteins such as PABP or ribosomal proteins) 
upon mTORC1 activation (Gandin et al., 2016; Masvidal et al., 2017; Thoreen et al., 2012). 
Mechanistically, this specific recognition of these mRNAs would depend on the mRNA binding 
protein La-Related Protein 1 (LARP1) as identified by a proteomic analysis of cap-associated proteins 
(Figure 9A) (Tcherkezian et al., 2014). Indeed, LARP1 would act as an adaptor for mTORC1-
sensitive TOP-mRNAs translation where it would recruit Raptor and thus mTORC1 to the specific 
mRNAs and lead to a spatially restricted phosphorylation of 4EBP1 and 2 and of S6K1, increasing 
the polysomal loading of these mRNAs and thus their translation (Hong et al., 2017). However, 
another study proposed another role of LARP1 which would act predominantly as a cap-binding 
protein showing an increased affinity for the TOP sequence and would compete with and displace 
eIF4E, disrupting the eIF4F complex. In this model, mTORC1 phosphorylation of LARP1 would 
therefore have an inhibitory effect on LARP1 (Figure 9B) (Fonseca et al., 2015; Lahr et al., 2017). In 
addition, mTORC1 would also promote the specific translation of mRNAs containing TOP-like 
motif, which consist of a minimum 5 pryrimidines located within four nucleotides of the main 
transcriptional start site. This more permissive definition of TOP motif thus enlarge the repertory of 
TOP mRNAs with additional translation-related proteins such as all ribosomal proteins but for 
RPS27A which presents extra-ribosomal functions (Thoreen et al., 2012). 
 Several non-TOP containing mRNAs have also been described to be sensitive to mTORC1 
inhibition by rapamycin (Gandin et al., 2016; Masvidal et al., 2017). Among non-TOP mRNA two 
types of transcripts are found: either long-5’UTR transcripts, mainly pro-survival and cell-cycle 
associated transcripts (cyclins, Bcl-2, Myc, …), sensitive to eIF4E and eIF4A inhibition; or short-
5’UTR transcripts, mainly mitochondrial transcripts enriched for TISU (Translation Initiator of Short 
5’UTR) elements (ATP5O, ATP5G1, UQCC2, …), sensitive to eIF4E inhibition but not to eIF4A 
inhibition (Gandin et al., 2016; Masvidal et al., 2017). Indeed, eIF4A has been described to promote 
the translation of a subset of mRNAs (mainly pro-survival and cell cycle-associated transcripts like 
Myc or Bcl-2) containing particular structures in their 5’UTR, called G-quadruplexes and consisting 
in a minimal four repetition of CGG (Wolfe et al., 2014). The targeted mRNAs are thus sensitive to 
eIF4A inhibition and present long and complex 5’UTR as described above (Gandin et al., 2016; Wolfe 




Figure 10. eIF4E export function model of growth promoting mRNAs (Volpon et al., 2017).  eIF4E and its adaptor protein 
LRPPRC enter the nucleus with the importin 8 entry pathway and upon 4E-SE recognition, LRPPRC binds the target mRNAs and associates with 
eIF4E, binds to the cap of target mRNAs. Additionally, LRPPRC binds the nuclear export protein CRM1 and allows the export of the whole 














Mechanistically, the activity of mTOR depends on its phosphorylation. The serine residues S2448 
and S2481 are associated with active mTORC1 and mTORC2, respectively, and can be used as 
mTORC1 and 2 activity markers. The phosphorylated S2448 is part of a feed-forward loop and is 
targeted by S6K or AKT while the second one, less specific, would result from autophosphorylation 
(Copp et al., 2009; Inoki et al., 2002). Another specificity concerns Raptor phosphorylation on serine 
863 and 859, necessary for mTORC1-associated mTOR activity. Indeed, both phosphorylations are 
insulin-dependent and are achieved by mTOR in a way similar to 4EBP1 and S6K1 phosphorylation, 
while the p-S863 would allow the stabilization of Rheb-mTOR activating interaction and allow the 
closeness of TOS-containing mTORC1 specific targets, increasing their mTOR directed 
phosphorylation (L. Wang et al., 2009).  
 
9. Another branch of eIF4E-4EBP1 axis: eIF4E mRNA export function 
 
In addition to its specific cap-dependent translation activity, eIF4E has been described to ensure a 
second activity: the export activity of specific mRNAs out of the nucleus. This specific activity has 
been first described for the specific export of the cyclin D1 mRNA in NIH3T3, U2OS and HEK293T 
cell lines (Culjkovic et al., 2005). This specific export is achieved thanks to the presence of a 50 
nucleotides sequence in the 3’UTR of this mRNA, called the 4E-Sensitive Element (4E-SE) sequence, 
that additionally requires eIF4E cap binding. It is principally the secondary structure (adjacent Stem 
Loop Pairs) formed by this sequence which is important for eIF4E specific recognition. 4E-SE is 
found in several transcripts which mainly encode for proteins involved in cell growth. The biological 
effect of the increased export of specific mRNAs is correlated with increased protein level of the 
corresponding mRNAs (Culjkovic et al., 2006). Some mRNAs are also both specifically transported 
and translated such as the ODC which possesses both the 3' and 5' UTRs structures sensitives to the 
nuclear and cytoplasmic functions of eIF4E, respectively (Culjkovic et al., 2007).  
 Nijmegen Breakage Syndrome 1 (NBS1) mRNA is also specifically exported thanks to its 4E-SE. 
NBS1 is involved in AKT pathway since increase in its protein expression leads to an increased AKT 
activation. This mechanism leads notably to an increased phosphorylation of 4EBP1, leading to an 
upregulation of eIF4E translational activity (Culjkovic et al., 2008). The transcription factor Myc, a 
positive transcriptional regulator of eIF4E (Raught & Gingras, 1999), is also specifically exported, 
thereby providing a positive feedforward loop for eIF4E expression and activity, possibly involved 
in the oncogenic potential of eIF4E (Osborne & Borden, 2015).  
Therefore, due to this export function, eIF4E presents both a cytoplasmic and nuclear localization. 
In the nucleus, eIF4E has been described to form nuclear bodies, as well as PML (Lallemand-
Breitenbach & de Thé, 2018). In addition, to its transcriptional regulator function, PML would 
sequestrate eIF4E in these nuclear bodies, thus acting as a potent inhibitor of eIF4E export activity of 
specific mRNAs. Indeed, PML can associate with eIF4E and inhibits its mRNA export activity due 
to the 100-fold decreased eIF4E cap affinity, the cap binding being necessary for the mRNA export 
(Culjkovic et al., 2006; Osborne & Borden, 2015; Volpon et al., 2017). PML interacts with eIF4E 
using its RING domain, which usually binds zinc residues, and binds eIF4E nearby the common 
eIF4E binding motif in the dorsal part of the protein (Cohen et al., 2001). 
 To complete this model, the Leucine-rich PPR motif-containing protein (LRPPRC), a 
mitochondrial and nuclear protein, is the adaptor protein required for eIF4E export activity (Figure 
10) (Osborne & Borden, 2015; Topisirovic et al., 2009). Indeed, LRPPRC contributes to localize 
eIF4E to the nucleus and competes with PML for the nuclear form of eIF4E, leading to the loss of its 
PML-dependent inhibition. LRPPRC binds eIF4E thanks to two consensus eIF4E binding sites and 
binds an overlapping region of the common binding site over eIF4E (Topisirovic et al., 2009). 
Moreover, LRPPRC binds the 4E-SE element on one hand and eIF4E on the other hand and 




recycling pathway of eIF4E and its associated protein LRPPRC allowing for their nuclear entry 
corresponds to the importin 8 pathway (Figure 10) (Volpon et al., 2017). 
eIF4E would also be involved in the recognition and direct binding of particular 4E-SE element 
found in the coding sequence of histone H3 and H4 mRNA and not in their 3’UTR. Indeed, the amino-
terminal domain of eIF4E would be involved in this binding, necessary for the particular translation 
initiation mechanism of these mRNAs. Mechanistically, eIF4E recognizes the internal secondary 
structure of the mRNA and allows the assembly of the ribosome. The folding of the mRNA ensures 
eIF4E binding to the cap and thus eIF4A recruitment, required for the inhibitory three-way helix-
unwinding of the mRNA leading to its translation (Martin et al., 2011). 
Another important feature is that 4EBPs themselves are also able to induce the nuclear localization 
of eIF4E in response to cellular stresses. Indeed, an increase in the nuclear form of eIF4E, bound to 
4EBP1, has been observed in response to heat shock (Sukarieh et al., 2009) or starvation (Rong et al., 
2008). The 4EBP3 isoform has also been described as a potent inhibitor of the specific mRNA export 
activity of eIF4E since at least 40% of 4EBP3 are found in the nucleus (compared with maximum 
30% for 4EBP1) (Kleijn et al., 2002). This 4EBP3 function has been described for different mRNAs 




The overall objective of this work was to characterize the potential translational regulation 
involved in the mitochondrial remodeling occurring during the hepatogenic differentiation of BM-
MSCs. In a first step, we have focused on the eIF4F complex, as preliminary data indicate a 
downregulation of 4ENP1 abundance during BM-MSC hepatogenic differentiation (see Introduction, 
point I.5). We began to evaluate the protein abundance of the cap binding protein eIF4E and of its 
partners eIF4G and 4EBP1 during the differentiation process. In addition, the functional activity of 
the eIF4F complex has been assessed.   
  In a second step, 4EBP1 upstream regulators have been explored, and more precisely the mTOR 
regulatory pathway. The phosphorylation status of 4EBP1 during the differentiation process, in 
addition with the assessment of S6K1 phosphorylation during the hepatogenic differentiation have 
been assessed, giving functional information about the activity of mTORC1 pathway during the 
process. In addition, to further evaluate the translational level during the differentiation, global protein 
synthesis measurement has been done.   
  Finally, a potential nuclear function of the eIF4E-4EBP1 axis has been explored by the 
characterization of the subcellular localization of both eIF4E and 4EBP1. Altogether these results 


















Figure 11. Differentiation protocol and workflow for hepatogenic differentiation of hBM-MSCs (Wanet et al., 2014). The 
differentiation process takes place in 22 days with sequential exposure of the cells to three cytokine cocktails, allowing respectively differentiation 
induction, hepatic induction and hepatic maturation. Upon confluency, expanding cells (“Exp”) are either exposed to cytokine-containing 














III. MATERIALS AND METHODS 
 
1. Cell culture and differentiation 
 
Human bone marrow-derived mesenchymal stem cells (hBM-MSC) were obtained from healthy 
and consenting donor and were isolated in Jules Bordet institute (thanks to a collaboration with Dr M. 
Najar laboratory of Clinical Cell Therapy, Jules Bordet Institute). The donors are represented here 
with the “BM” notation followed by a number, the passage is indicated with the “P” notation after 
the donor identification. Expanding hBM-MSCs (referred to as “Exp” in the present manuscript) were 
cultivated at 37°C and 5% CO2 in DMEM (Dulbecco's Modified Eagle's Medium) 1g/L glucose 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% Fetal Bovine Serum 
(FBS) (Gibco), 100 U/mL penicillin and 100 µg/L streptomycin (Gibco). Expanding cells were 
seeded at ~4000 cells/cm2 and passaged every 3-7 days depending on the donor (to avoid reaching 
confluency). Cells used for differentiation were from passages 3-7 and were seeded on surfaces 
previously coated by incubation of 0,02M filtered acetic acid containing 50 µg/mL rat tail collagen 
type 1 (354236, VWR International, Radnor, PA, USA) during 2h at 37°C.   
 The differentiation process was performed as previously described in (Najar et al., 2013) and 
illustrated in Figure 11. Briefly, cells were seeded on collagen-coated surfaces at a density of 10 000 
cells/cm2. When confluent, this corresponds to the experimental condition called “Day 0”. The 
differentiation was then started when cells (Diff condition) were cultivated in IMDM containing 
(Iscove’s Modified Dulbecco Medium, Gibco) 100 U/mL penicillin and 100 µg/mL streptomycin 
supplemented with 20 ng/mL EGF (PeproTech, Rocky Hill, NJ, USA) and 10 ng/mL fibroblast 
growth factor-2 (FGF-2) (PeproTech) for the first two days (differentiation initiation). For the 10 
following days (hepatic induction), the medium was supplemented with 10 ng/mL FGF-2, 20 ng/mL 
hepatocyte growth factor (HGF) (PeproTech), 0,61 mg/mL Nicotinamide (Sigma-Aldrich, Saint-
Louis, MO, USA) and 1X insulin-transferrin-selenium (ITS) (Thermo Fisher Scientific). The medium 
was renewed at days 5 and 9. For the last 10 days (hepatic maturation), the medium was supplemented 
with 20 ng/mL OSM (PeproTech), 1 µM Dexamethasone (Sigma-Aldrich) and 1X ITS. The medium 
was renewed at days 15 and 19. The undifferentiated hBM-MSC (Undiff condition) were seeded at 
the same density and followed the same kinetics as the Diff condition but were cultivated in IMDM 
supplemented with 1% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin. 
 
2. Western Blot analyses 
 
Cells cultured in T25 and T75 flasks were washed once with Phosphate Buffer Saline (PBS) (pH 
7,4), trypsinized and centrifuged at 300xg for 5 minutes. The cell pellets were stored at -80°C or 
directly lysed in DLA-MITO lysis buffer (7M Urea; 2M Thiourea; 1% CHAPS; 1% ASB-14; 30 mM 
Tris HCl pH 7,6 and 1% Sodium Dodecyl Sulfate) complemented with Complete Protease Inhibitor 
Cocktail (#04693116001; Roche, Basel Switzerland) and homemade phosphatase inhibitor cocktail 
(25 mM Na3VO4 [S-6508, Sigma-Aldrich]; 250 mM 4-nitrophenylphosphate [N-3254, Sigma-
Aldrich]; 250 mM di-Sodium β-glycerophosphate pentahydrate [27874295, VWR] and 125 mM NaF 
[6449/106441, Merck Millipore]). Cell lysates were incubated 15 minutes on a thermomixer at 12°C 
with 500RPM followed by 3x 10 seconds sonication at 50% amplitude-Pulse 1. Afterwards the lysates 
were centrifuged at 14000xg at 12°C for 15 minutes, the supernatants were collected and protein 
concentration was assessed with the Pierce protein assay reagent (Thermo Fisher Scientific) 




8 or 10 µg of proteins were resuspended in equal volumes of Western Blot loading buffer (0,5 M 
Tris pH 6,8, SDS, β-mercaptoethanol, glycerol) prior to loading on home-made SDS-polyacrylamide 
gels composed of a layer of 6% acrylamide gel on top of a layer of 15% acrylamide gel. Color 
Prestained Protein Standard, Broad Range (11–245 kDa) was used as protein ladder (New England 
Biolabs, Ipswich, MA, USA). Protein migration was performed at 120-150V during approximately 
1h (until frontline reaches the bottom of the gel) into Mini-PROTEAN Tetra Cell (BioRad, Hercules, 
CA, USA). Proteins were transferred on PolyVinyliDene Fluoride (PVDF) (Immobilon-P, Merck 
Millipore) membranes using either Trans-Blot Turbo Transfer System (BioRad) (25V, 1,3A, 10 
minutes) or liquid transfer (100V, 2h30). Membranes were blocked by incubation in 50% Odyssey 
Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA)-PBS during at least 1h at Room 
Temperature (RT) on rocker prior probing with primary antibodies overnight at 4°C or 1h at RT on 
rocker. Secondary fluorescent antibodies were incubated 1h at RT. Primary and secondary antibodies, 
listed in Table 2, were diluted in Odyssey Blocking Buffer (LI-COR Biosciences) 0,1% Tween-20 
(BioRad, USA). Membrane fluorescence was detected using Odyssey Licor Scanner (LI-COR 
Biosciences) and fluorescent signals were quantified using the Odyssey Application Software 
Version 3.0 of LI-COR Biosciences. All quantifications are expressed in relative protein abundance 
after normalization of the fluorescence intensity of each protein of interest over its corresponding 
loading control fluorescence. The ratio was then reported to day 0 condition signal. 
 
Western-Blot-Primary antibodies 
Target Manufacturer Reference Specie Dilution 
eIF4E (P-2) Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) sc-9976 Mouse monoclonal 1:1000 
eIF4G (A-10) Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) sc-133155 Mouse monoclonal 1:1000 
ATP synthase β (3D5AB1) Thermo Fisher Scientific (Waltham, MA, USA) A-21351 Mouse monoclonal 1:1000 
ATP synthase α (7H10BD4F9) Thermo Fisher Scientific (Waltham, MA, USA) 459240 Mouse monoclonal 1:1000 
Lamin A/C BD Biosciences (Franklin Lakes, NJ, USA) 612162 Mouse monoclonal 1:1000 
Puromycin (12D10) Merck Millipore (Burlington, MA, USA) MABE343 Mouse monoclonal 1:5000 
4EBP1 (53H11) Cell Signaling Technology, Inc. (Danvers, MA, USA) 9644 Rabbit monoclonal 1:2000 
Histone H3 (D1H2) Cell Signaling Technology, Inc. (Danvers, MA, USA) 4499 Rabbit monoclonal 1:4000 
GAPDH (EPR6256) Abcam (Cambridge, UK) 128915 Rabbit monoclonal 1:1000 
LDHA Cell Signaling Technology, Inc. (Danvers, MA, USA) 2012 Rabbit monoclonal 1:1000 
Phospho-p70 S6 Kinase (Thr389) Cell Signaling Technology, Inc. (Danvers, MA, USA) 9205 Rabbit monoclonal 1:1000 
Phospho-eIF4E (Ser209) Cell Signaling Technology, Inc. (Danvers, MA, USA) 9741 Rabbit monoclonal 1:1000 
Phospho-mTOR (Ser2448) Cell Signaling Technology, Inc. (Danvers, MA, USA) 2971 Rabbit monoclonal 1:1000 
Phospho-4EBP1 (Thr37/46) (236B4) Cell Signaling Technology, Inc. (Danvers, MA, USA) 2855 Rabbit monoclonal 1:2000 
p70 S6 Kinase Cell Signaling Technology, Inc. (Danvers, MA, USA) 9202 Rabbit monoclonal 1:1000 
Phospho-eIF2α (Ser51) Cell Signaling Technology, Inc. (Danvers, MA, USA) 9721 Rabbit monoclonal 1:1000 
NDUFS6 Abcam (Cambridge, UK) 195807 Rabbit monoclonal 1:1000 
Western-Blot-Secondary antibodies 
Targeted specie Manufacturer Reference Specie Dilution 
Mouse (IR Dye 800CW) LI-COR Biosciences (Lincoln, NE, USA) 926-32210 Goat polyclonal 1:10000 
Rabbit (IR Dye 800CW) LI-COR Biosciences (Lincoln, NE, USA) 926-32211 Goat polyclonal 1:10000 
Mouse (IR Dye 680RD) LI-COR Biosciences (Lincoln, NE, USA) 926-68070 Goat polyclonal 1:10000 
Rabbit (IR Dye 680RD) LI-COR Biosciences (Lincoln, NE, USA) 926-68071 Goat polyclonal 1:10000 
Immunofluorescence-Primary antibodies 
Targeted protein Manufacturer Reference Specie Dilution 
4EBP1 (53H11) Cell Signaling Technology, Inc. (Danvers, MA, USA) 9644 Rabbit monoclonal 1:1500 
eIF4E (P-2) Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) sc-9976 Mouse monoclonal 1:100 
TOM20 (FL-145) Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) sc-11415 Rabbit polyclonal 1:100 
Immunofluorescence-Secondary antibodies 
Targeted specie Manufacturer Reference Specie Dilution 
Mouse (Alexa fluor 488 nm) Thermo Fisher Scientific (Waltham, MA, USA) A-11001 Goat polyclonal 1:1000 
Rabbit (Alexa fluor 488 nm) Thermo Fisher Scientific (Waltham, MA, USA) A-11008 Goat polyclonal 1:1000 
Rabbit (Alexa fluor 647 nm) Thermo Fisher Scientific (Waltham, MA, USA) A-21244 Goat polyclonal 1:1000 






 Exp, differentiated and undifferentiated hBM-MSCs were trypsinized prior to seeding on sterilized 
coverslips (coated with collagen for differentiated and undifferentiated cells) at 20 000 cells/cm2 in 
24-wells plates. On the next day, cells were washed 3x with PBS, fixed by a 10 minutes incubation 
with 4% paraformaldehyde and permeabilized 5 minutes with 1% Triton X-100 in PBS. Cells were 
then washed 3x with PBS containing 2% Bovine Serum Albumin (BSA) Protease Free (422361V, 
VWR) (hereafter called PBS-2% BSA) and incubated overnight at 4°C with primary antibodies 
diluted in PBS-2% BSA. After 3 additional PBS-2% BSA washes, cells were incubated 1h at RT with 
secondary antibodies diluted in PBS-2% BSA and then washed twice with PBS-2% BSA and once 
with PBS. Afterwards, cells were incubated 20 minutes in PBS supplemented with 1 µg/mL 4′,6-
diamidino-2-phenylindole (DAPI) (1023627001, Sigma-Aldrich) to stain nuclei, and then washed 
thrice with PBS. Primary and secondary antibodies are listed in Table 2. Coverslips were then 
mounted on slides using Mowiol (4-88, Sigma-Aldrich) and left to harden overnight at 4°C. Confocal 
microscopy analyses were performed using Leica Confocal Microscope (Leica microsystem, Wetzlar, 
Germany). 
 
4. Periodic Acid Schiff (PAS) Staining 
 
PAS staining was performed using the Sigma-Aldrich PAS Kit (395B-1KT). Cells at the end of 
the differentiation process (Day 22) were trypsinised and seeded on collagen-coated sterilized 
coverslips at 45 000 cells/cm2 in 24-wells plates. Cells were then washed 3x using PBS and fixed 
with 4% paraformaldehyde for 20 minutes, incubated with 1% periodic acid for 10 minutes, washed 
3x with ddH2O and then incubated for 15 minutes with Schiff reagent. Coloration was then developed 
by 10x tap water washes for 10 minutes with 1 wash/minute. Coverslips were mounted on slides using 
Mowiol and left to harden overnight at 4°C in the dark, before observation with phase contrast 
microscope. 
Table 3. Primers used for RT-qPCR. 
  
5. Cellular fractionation, RNA and protein extraction 
 
 Nuclear and cytosolic fractions were prepared according to (Tacheny et al., 2012). All steps for 
cellular fractionation were performed at 4°C. Briefly, hBM-MSCs cultured in T150 flasks were rinsed 
Genes  Forward Primers (5’        3’) Reverse Primers (3’        5’) 
SOX9 (SRY-Box 9) CACACAGCTCACTCGACCTTG TTCTTCGGTTATTTTTAGGATCATCTC 
TDO2 (Tryptophan 2,3-dioxygenase) GAGGAACAGGTGGCTGAATTT GCTCCCTGAAGTGCTCTGTA 
α1AT (Alpha-1 Antitrypsin) GGGTCAACTGGGCATCACTAA CCCTTTCTCGTCGATGGTCA 
TBX3 (T-box transcription factor 3) GTCGGGAAGGCGAATGTTTC ACGACAGTCATCAGCAGCTA 
PPIE (Peptidyl-prolyl cis-trans isomerase E) CCGCTCTTGACCCTGCATAT TCCAAGCAGACCCTGAGGAA 
DDIT4 (DNA Damage Inducible Transcript 4) CTAGCCTTTGGGACCGCTTC CCAGGTAAGCCGTGTCTTC 
GAPDH (Glycéraldéhyde-3-phosphate déshydrogénase) CGGAGTCAACGGATTTGGTC TGGAATTTGCCATGGGTGGA 
ND2 (NADH dehydrogenase subunit 2) TGTTGGTTATACCCTTCCCGTACTA CCTGCAAAGATGGTAGAGTAGATGA 
TBP (TATA box binding protein) TCCCGCCTGGTGCCCTACTC CGCCCAGCCAGCCAGTAGTA 
EIF4EBP1 (eIF4E-binding protein 1) CAAGGGATCTGCCCACCATT AACTGTGACTCTTCACCGCC 
CCND1 (cyclin D1) CCATGAACTACCTGGACCGC TGAAATCGTGCGGGGTCATT 
ODC1 (Ornithine decarboxylase 1) TGATGCCCGCTGTGTTTTTG AACTGCAAGCGTGAAAGCTG 
VEGFA (Vascular endothelial growth factor A) CCATCCAATCGAGACCCTGG TCTCTCCTATGTGCTGGCCT 
HSPA9 (mitochondrial Heat Shock Protein 70) CTGAAGAAGACCGGCGAAAGA AGCTTGTTGCACTCATCAGCA 
EGR1 (Early growth response 1) TGACCGCAGAGTCTTTTCCT GTTTGGCTGGGGTAACTGGT 
ATF4 (Activating Transcription Factor 4) GCCAAGCACTTCAAACCTCA GCATCCTCCTTGCTGTTGTT 
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and then incubated 20 minutes with Hypotonic Buffer (HB) (5 mM NaF, 1 mM Na2MoO4, 20 mM 
HEPES [pH 7,9] and 0,1 mM EDTA) prior to lysis by addition of lysis buffer (HB supplemented with 
0,5% Nonidet P-40 and 100 U/mL RNAINH-RO [Roche]) and scraping for 5 minutes. One-fifth of 
the cell homogenate was saved as the total fraction. The cell homogenate was centrifuged at 14000xg 
at 4°C for 30 seconds and the supernatant was collected as cytoplasmic fractions. The nuclear pellets, 
corresponding to nuclear fractions, were resuspended in a defined volume of lysis buffer (e.g. 400 µL 
for 1x T150 flask). The same volume of supernatant fractions (in excess) and total fractions (that 
needed completion with lysis buffer to reach the volume) were used for protein and RNA extraction. 
Three volumes of TRI Reagent Solution (AM9738, Thermo Fisher Scientific) were added to each 
fraction (total, nuclear and cytoplasmic) which were left for 5 minutes incubation at RT. One-fifth 
volume of chloroform was then added to each fraction, mixed by inversion, and left for 5 minutes 
incubation at RT prior to centrifugation at 12 000xg at 4°C for 15 minutes, allowing for the formation 
of three phases. For RNA extraction, the upper phase was collected and transferred in a new tube. 
One volume of isopropanol was added, the two remaining phases were saved for protein extraction 
(see below).  
For the RNA extraction, the three fractions were let to incubate 10 minutes at RT with the 
isopropanol and were then centrifuged at 12 000xg at 4°C for 10 minutes. The RNA pellets were then 
washed with 100% and 75% ethanol sequentially, then left to air dry prior resuspension in nuclease-
free water. RT-qPCR was then performed on each sample as described below (the used primers are 
listed in Table 3).  
For protein extraction, 100% ethanol was added to the remaining phases for each fraction, left 
incubate 3 minutes at 4°C and centrifuged at 2000xg at 4°C for 5 minutes. The supernatant was then 
saved and isopropanol was added, let incubate 10 minutes at 4°C and centrifuged at 12 000xg at 4°C 
for 10 minutes. Protein pellets were then washed thrice with 0,3 M guanidinium chloride 
(1.04219.0100/104220, Merck Millipore) in 95% ethanol and once with 100% ethanol. Protein pellets 
were then let to air dry and then resuspended in DLA-MITO buffer (see Western Blot analyses). 
Fractionation efficiency was assessed by Western-blot detection of Lamin A/C and Lactate 
Dehydrogenase A (LDHA) as nuclear and cytoplasmic markers, respectively. 
 
6. RNA extraction and RT-qPCR 
 
RNA was extracted using the RNeasy Mini kit and QIACube device (Qiagen, Venlo, The 
Netherlands). Reverse transcription was performed using the Promega GoScript Reverse 
Transcriptase kit (A2791, Promega, Fitchburg, WI, USA) (250-1000 ng of extracted RNA was 
engaged, depending on the available material and extraction yield) and quantitative Real-Time PCR 
(Rt-qPCR) was then achieved using the Gotaq qPCR Master Mix (A6002, Promega) with ViiA 7 
Real-Time PCR System (Thermo Fisher Scientific). The used primers are listed in Table 3. Results 
were normalized with the ddCT method using PPIE (Peptidyl-prolyl cis-trans isomerase E) mRNA 
abundance as housekeeping gene and reported to Day 0 condition mRNA abundance. 
 
7. Cap binding assay 
 
Cap binding assay protocol was adapted from (Tahmasebi et al., 2016). This method consists in 
the specific pull-down of eIF4E and bound partners using mRNA cap analogous-coated beads 
(Bradley et al., 2002). At indicated timepoints, hBM-MSCs were washed once with PBS, trypsinized 
and centrifuged at 300xg for 5 minutes. Cell pellet was then resuspended in buffer A (lysis buffer) 
(50 mM MOPS-KOH pH 7,4; 100 mM KCl; 0,02 mM NaN3; 0,5 mM EDTA; 1% Nonidet P-40; 1% 
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sodium deoxycholate supplemented with cOmplete™, EDTA-free Protease Inhibitor Cocktail 
[#11873580001, Roche]) and incubated 10 minutes on ice. The lysate was then centrifuged at 
16 000xg for 10 minutes and the supernatant was transferred in a new tube, on ice. 2% of total lysate 
was saved as the “Input” sample for Western Blot analysis. A fraction corresponding to 500 µg of 
protein lysate was added to x µL of buffer B in order to reach a final volume of 1 mL (MOPS-KOH 
pH 7,4 50 mM; KCl 100 mM; NaN3 0,02 mM; EDTA 0,5 mM, and EDTA-free Complete Protease 
Inhibitor Cocktail) prior incubation with immobilized γ-aminophenyl-m7GTP (C10 spacer) beads 
(AC-155S, Jena Bioscience, Germany) for 2h on rotating wheel at 4°C. Beads were then washed 5x 
with buffer B and bound proteins were then eluted with 0,2 mM m7GTP (NU-1122S, Jena Bioscience) 
for 15 minutes at 4°C on thermocycler at 500 RPM. Beads were centrifuged at 4500xg for 30 seconds 
at 4°C. The supernatant corresponding to eluate was collected and analyzed by Western Blot to assess 
the abundance of eIF4E, eIF4G and 4EBP1. Detection of Glyceraldehyde-3-phosphate 
Dehydrogenase (GAPDH) was used as a negative control. 
 
8. mtDNA content evaluation 
 
 Total DNA was extracted using the Wizard Genomic DNA Purification Kit (A1120/ A1125/ 
A1620, Promega). Mitochondrial DNA content was assessed by qPCR using primers targeted against 
the mitochondria-encoded gene NADH dehydrogenase subunit 2 (ND-2) and was normalized to 
genomic DNA by using primers targeted against the genomic gene TATA-Binding Protein (TBP) 
(Table 3). qPCR was performed using the Gotaq qPCR Master Mix with ViiA 7 Real-Time PCR 
System. Relative mtDNA content was normalized over Day 0 condition. 
 
9. Global translation measurement 
 
Global translation was assessed by surface sensing of translation (SUnSET) as described in (E. K. 
Schmidt et al., 2009).  hBM-MSCs were incubated for 10 minutes in medium supplemented with 5 
µg/mL puromycin dihydrochloride from Streptomyces alboniger (P88-33, Sigma-Aldrich). The 
puromycin is a well-known analog of amino-acyl-tRNA which is incorporated in the nascent chain 
during translation. However, once incorporated, puromycin prevents translation elongation, thereby 
triggering premature translation termination (Blanco & Blanco, 2017). For negative controls, cells 
were previously incubated 30 minutes in the presence of 20 µg/mL cycloheximide (C7698-1G, 
Sigma-Aldrich) or underwent a medium replacement without puromycin. Cells were then lysed in 
DLA-MITO (see Western Blot analyses) and global protein synthesis was assessed by western-blot 
(as previously described in E. K. Schmidt et al., 2009). 10 µg of proteins were resolved on 10% 
acrylamide gel and puromycin was detected with monoclonal anti-puromycin antibody (Table 2). For 
each condition, signal intensity was normalized over histone H3 signal. 
 
10. Statistical analyses 
 
 All the statistical analyses were performed using the statistical programming language R 
(www.rproject.org/) with the “ggplot2” and “ggpubr” packages. Assuming normal distribution of the 
data, unpaired two-tailed t-tests were performed for the comparison between Diff and Undiff 
conditions for each time point but for SOX9 expression in Figure 12D where day 22 Diff and Undiff 
conditions were also compared to EXP and Day 0 condition. Bonferroni correction was applied for 





Figure 12. Assessment of differentiation efficiency based on cell morphology, PAS staining and gene expression on three different donors. 
The differentiation was performed on three different donors namely: (A) BM18P6, (B) BM2P7 and (C) BM22P7, cited hereafter donor 1, donor 2 
and donor 3 respectively.  Cells were seeded at 10 000 cells/cm2 following the differentiation protocol described in (Najar et al., 2013) with 
sequential exposure of the cells to three different cytokine cocktails: EGF and FGF-2 for the first two days; FGF-2, HGF, Nicotinamide and ITS 
for the next ten days; OSM, dexamethasone and ITS for the last ten days, responsible for differentiation initiation, hepatic induction and maturation 
steps respectively (Figure 11). Cell micrographs were taken when medium was replaced and the cytokine cocktail changed, at Day 2, 12 and 22. 
For each donor, Periodic Acid Schiff staining was performed on cells in expansion (Exp.) (for donors 2 and 3) and at the end of the process on 
differentiated (Diff.) and undifferentiated (Undiff.) cells. Cells were seeded on coverslips at a density of 45 000 cells/cm2 and underwent PAS 
staining, highlighting glycogen accumulation with granule-like staining, indicated by the black arrows. Scale bar = 50 μm. (D) RNA extraction 
was performed on cells in expansion and on differentiating and undifferentiated cells collected at day 0, 2, 3, 5, 9, 12, 15 and 22 of differentiation. 
Expression of hepatic (α-1-antitrypsine (α1AT), tryptophan 2,3-dioxygenase (TDO2)), developmental (T-box Transcription factor 3 (TBX3)) and 
stemness markers (SRY-Box 9 (SOX9)) was assessed using Real-time PCR. mRNA abundance of each gene is normalized to PPIE (Peptidyl-prolyl 
cis-trans isomerase E) and then expressed relatively to day 0 ratio. The profile of α1AT corresponds to the one of the first donor represented in A 
(n=1), TDO2 values are represented as mean of donors 1 and 2 (n=2) and data for TBX3 and SOX9 are presented for the three donors as mean ± 
SEM (n = 3). Unpaired two-tailed t-test were performed for each timepoint, comparing Diff with Undiff conditions and comparing EXP and Day 












Figure 12. (following). Assessment of differentiation efficiency based on cell morphology, PAS staining and gene expression on three 
different donors. (D) RNA extraction was performed on cells in expansion and on differentiating and undifferentiated cells collected at day 0, 2, 
3, 5, 9, 12, 15 and 22 of differentiation. Expression of hepatic (α-1-antitrypsine (α1AT), tryptophan 2,3-dioxygenase (TDO2)), developmental (T-
box Transcription factor 3 (TBX3)) and stemness markers (SRY-Box 9 (SOX9)) was assessed using Real-time PCR. mRNA abundance of each 
gene is normalized to PPIE (Peptidyl-prolyl cis-trans isomerase E) and then expressed relatively to day 0 ratio. The profile of α1AT corresponds 
to the one of the first donor represented in A (n=1), TDO2 values are represented as mean of donors 1 and 2 (n=2) and data for TBX3 and SOX9 
are presented for the three donors as mean ± SEM (n = 3). Unpaired two-tailed t-test were performed for each timepoint, comparing Diff with 















Figure 13. Assessment of mitochondrial remodeling at the protein level. (A) Cells corresponding to the three different donors presented in 
Figure 12 followed a complete differentiation program. Exp, Diff and Undiff cells were collected at the indicated time-points for proteins 
extraction. 8 μg of proteins were loaded on four 6-15% polyacrylamide gels, where for each gel, Exp and Day 0 samples were loaded as control. 
ATP5B, ATP5A, NDUFS6 and histone H3, the loading control, were detected. (B) Quantification of the signal intensity of the different proteins 
was normalized with the histone H3 signal and then with the ratio calculated for day 0 to obtain relative protein abundance. Data are presented as 
mean ± SEM (n = 3). Unpaired two-tailed t-test were performed for each timepoint, comparing Diff with Undiff conditions. (C) Exp, Diff and 
Undiff cells of donor 2 and 3 were collected at the indicated time-points and DNA extraction was performed to assess TATA-Binding Protein 
(TBP) and ND2 (NADH dehydrogenase subunit 2) gene abundance, as nuclear and mitochondrial genomic markers, respectively. ND2 gene 







1. Hepatogenic differentiation efficiency assessment 
 
 Although the hepatogenic differentiation model of hBM_MSC has been previously described 
(Wanet et al., 2014), three different read-outs were selected to assess the efficiency of cell 
differentiation: the cell morphology, the glycogen storage ability (assessed at the end of the process), 
and the evolution of mRNA markers during the process. Results for three independent differentiation 
processes performed on independent donors, further referred as donors 1, 2 and 3, are presented on 
Figure 12. Morphologically, expanding BM-MSCs show fibroblast-like phenotype which is 
maintained upon confluency and in undifferentiated cells all along the differentiation process. On the 
other hand, upon differentiation induction, cells acquire a more elongated phenotype following 
exposure to the first and second cytokine cocktails, corresponding to the differentiation induction and 
hepatic induction steps, respectively (Figure 11). Hepatic maturation then occurs, following the 
exposure to the third cytokine cocktail, where cells shrink and become more cuboid with polygonal-
like shapes at the end of the process, typical of hepatocyte-like cells.  
  For the functional assessment of the differentiation efficiency, Periodic Acid Schiff (PAS) staining 
was performed at the end of the process, highlighting glycogen accumulation. PAS reaction leads to 
the non-discriminate staining of carbohydrates and thus only granule-like staining is informative. 
Such staining is only observed in differentiated cells and corresponds to glycogen granules 
accumulated in the cytosol, as indicated by the arrows on Figure 12. Notably, only few cells, in the 
differentiated condition, are positives for the PAS staining, underlining a limited differentiation 
efficiency and confirming previous observations concerning the limitations of this in vitro 
differentiation model (Wanet et al., 2014). In addition, the number of PAS positive cells is also 
different between the three donors, suggesting donor-dependent responsivity to the differentiation 
protocol. 
Concerning the evaluation of mRNA markers, the four target genes selected correspond to two 
hepatic markers: the α-1-antitrypsine (α1AT), encoding the major circulating serine protease inhibitor 
produced by the liver, and the tryptophan 2,3-dioxygenase (TDO2)), encoding an enzyme involved 
in tryptophan catabolism, more particularly in the early steps of the Kynurenine pathway and which 
is essentially produced in the liver (Jones et al., 2013); the developmental marker T-box Transcription 
factor 3 (TBX3) involved in liver development (Figure 3); and the stemness marker SRY-Box 9 (SOX9) 
maintaining cells in an undifferentiated state (Kawaguchi, 2013).   
  α1AT expression increases from day 12 to day 22 only in differentiating cells. However, α1AT 
expression profile could only be obtained for donor 1 due to technical issues for its assessment for 
donor 2 and 3. TDO2 expression profile shows similar feature with a continuous increase from day 2 
to day 12 as previously described (A. Wanet, PhD thesis). However, an unexpected decrease is 
observed with a consecutive increase from day 15 to day 22, where the expression of TDO2 in 
differentiated hepatocyte-like cells is still 25-fold higher than its expression in undifferentiated cells. 
The data for TDO2 represents results obtained for the two first donors as no amplification could be 
obtained for donor 3, in undifferentiated cells. Regarding TBX3 expression profile, an early 
significant increase is observed from day 0 to day 2, with a ~2-fold higher expression maintained in 
differentiating cells until day 12. TBX3 expression then decreases to reach similar levels than 
observed in undifferentiated cells. Finally, the stemness marker SOX9 shows higher expression in 
expanding cells compared with hepatocyte-like cells at day 22, while the expression level in 




Figure 14. Evolution of the eIF4F complex members abundance along the hepatogenic differentiation process. (A) Diff and Undiff cells 
from the previously mentioned three donors were collected at different time points and the expression of 4EBP1 was assessed by Real-Time PCR. 
(B) The protein abundance of 4EBP1 was also assessed, during the differentiation process for the three donors, using western blot, as for the other 
main components of the eIF4F complex: eIF4G and eIF4E. (C) Averaged quantification associated with the three blots in B. Quantification of the 
signal for each protein is normalized to the signal of its respective loading control (histone H3 signal) and is then expressed relatively to day 0 







2. Mitochondrial remodeling assessment 
 
In order to confirm the mitochondrial remodeling occurring during the hepatogenic differentiation 
of BM-MSC, the abundance of several mitochondrial proteins was analyzed (Figure 13). Despite 
variability between donors, displayed on the blots presented in Figure 13A, no straight abundance 
differences between differentiating and undifferentiated cells can be observed for the α subunit of the 
ATPase (ATP5A) while only a late but not significant difference can be observed for the β subunit 
(ATP5B) from day 15 to day 22. However, the NADH dehydrogenase (ubiquinone) iron-sulfur 
protein 6F (NDUFS6), an assembly factor of the mitochondrial respiratory complex I, shows a clear, 
although not significant, increased abundance in differentiating cells compared with undifferentiated 
ones in the three donors from day 3 to the end of the process, with a small drop at day 12. Despite the 
absence of significant differences, a consistent trend to increased abundance is observed regarding 
the signal intensities of the proteins on the blots (Figure 13A) and their associated individual 
quantifications per donor (Supplementary figure 1). Indeed, regarding the donors independently 
(Figure 13A, Supplementary figure 1A), a 2-3 fold difference is observed at day 22. Thus, due to 
different intensities in the differences between conditions, pooled information result in the 
disappearance of the biological effect which seems to exist regarding the consistency between the 
independent replicates. Two levels of variabilities are involved in this case: the variability linked to 
the donor and thus heterogenous cell population and the variability linked to the differentiation 
efficiency which shows inter-individual variability, meeting the first point, but also intra-individual 
variability. Therefore, three replicates are probably not enough to allow detection of a significant 
effect but describing general tendencies and looking at the data independently (Supplementary figure 
1) can help to draw observations and conclusions. In addition, the method used here is only a 
semiquantitative method whereas a quantitative and more sensitive method would give supplemental 
information. 
Another mitochondrial parameter has been further assessed to strengthen these results (Figure 
13C). Mitochondrial DNA (mtDNA) content was addressed during the differentiation process for 
donors 2 and 3 (Figure 13C). Once again variability between donors is observed as the increase in 
mitochondrial content in differentiating cells occurs earlier (around day 9) for donor 3, compared 
with donor 2 (around day 15). Interestingly, the protein abundance of NDFUS6 show the similar 
profile while regarding individually donor 2 and 3 (Supplementary figure 1A). 
 
3. Characterization of the eIF4F complex assembly during the differentiation process  
 
 Preliminary results obtained from the transcriptomic analysis performed after 5 days of 
differentiation suggest that 4EBP1 expression is downregulated in differentiating cells (see 
Introduction, point I.5). In order to validate 4EBP1 downregulation, its expression was analyzed all 
along the differentiation process (Figure 14A). Although no significant differences could be detected, 
due to the high inter-individual variability, a consistent profile for 4EBP1 can be observed with a 
downregulation from day 2 to day 12 and a subsequent upregulation till day 22 in differentiated cells 
compared with undifferentiated ones. This 4EBP1 expression profile is also observed at the protein 
level with the same variability between donors (Figure 14B), suggesting an increase in global protein 
synthesis followed by a decrease. However, this interpretation is not supported by the protein 
abundance of the eIF4F complex components, directly impacted by 4EBP1 activity. The eIF4G 
abundance profile is so different between donors that it can hardly by interpreted. Indeed, opposite 
effects are even observed for eIF4G expression at day 2 between donors 1 and 3 for example as its 
abundance is clearly downregulated in differentiating cells for donor 1 but slightly upregulated for 
donor 3 (Figure 14B). Importantly, the used antibody does only detect eIF4G1, the major isoform of 
eIF4G while the information concerning the other isoforms is not provided. In addition, the signal for 
 
 
Figure 15. Regulation of the eIF4F complex and mTORC1 activity assessment.  (A) Diff and Undiff cells from the previously mentioned 
three donors were collected at the indicated time points and the protein abundance of mTORC1-related proteins and targets was assessed by 














Figure 15 (following). Regulation of the eIF4F complex and mTORC1 activity assessment.  (B) Averaged quantification associated with the 
three blots in A. Quantification of the signal for each protein is normalized to the signal of its respective loading control (histone H3 signal) and 
is then expressed relatively to day 0 condition. Data are presented as mean ± SEM (n = 3). Unpaired two-tailed t-tests were performed for each 









this protein is really faint for some conditions and barely detectable, related to the poor sensitivity 
and quality of the used antibody. However, for the end of the differentiation process, a consistent 
profile is observed between the three different replicates, with a reduced abundance of the protein in 
differentiating cells compared with undifferentiated ones, suggesting a decrease in eIF4F complex 
assembly and thus of protein synthesis. Finally, the protein abundance of eIF4E remains globally 
unchanged all along the differentiation, in the two conditions (Figure 14C) with the sole exception of 
donor 2 where an upregulation is observed from day 12 to day 22 in differentiating cells, once again 
underlining the variability between donors (Figure 14B). 
 To get closer to functional characterization of eIF4F complex, the phosphorylation status of both 
eIF4E and 4EBP1 have been addressed, as well as the involvement of mTORC1 in the regulation of 
the eIF4E-4EBP1 axis (Figure 15). As for the total abundance of eIF4E, the abundance of phospho-
eIF4E (p-eIF4E) remains unchanged in both conditions during the differentiation process even if 
quantification of the donor 1 blot detects a peak in p-eIF4E abundance for undifferentiated cells at 
day 2, probably due to technical bias in the quantification of this condition (Figure 15B, 
Supplementary figure 1C). Similarly, the profile of p-4EBP1 abundance is parallel to the total form 
abundance profile with a decreased expression in differentiating cells compared with undifferentiated 
ones and, this time, a significantly reduced abundance at day 5, which is maintained till day 12, 
followed by an increase of p-4EBP1 in differentiated cells compared with undifferentiated one at day 
22. However, the decrease in the phosphorylation of 4EBP1 seems to be more pronounced than the 
decrease observed for the total form abundance, resulting in a lower fraction of phosphorylated 
4EBP1 in differentiating cells, highlighted by the p-4EBP1/4EBP1 ratio (Figure 15B). The reverse 
phenomenon is observed at the end of the process with the concomitant increase of the p-
4EBP1/4EBP1 ratio.   
  These results support the possible involvement of mTORC1 in the regulation of the eIF4E-4EBP1 
axis. This hypothesis has been next tested with the characterization of the S2448 phosphorylation of 
mTOR, associated with mTORC1 activity (Copp et al., 2009), along the process as well as the 
phosphorylated status of the other canonical target of mTORC1, S6K1. The S2448 phosphorylation 
of mTOR is reduced in differentiating cells compared with undifferentiated ones all along the 
differentiation process, with the difference between the two conditions begin more marked for donors 
1 and 3 (Figure 15A). This seemingly slightly reduced activation of mTORC1 is further confirmed 
following the phosphorylated status of S6K1. Indeed, a ~2-fold lower abundance of p-S6K1 is 
observed all along the differentiation process in differentiating cells, significantly validated at day 15. 
The total form of S6K1 follows the same profile. Therefore, the phosphorylated fraction of S6K1 is 
maintained identical between differentiating and undifferentiated cells all along the process (Figure 
15B). Altogether these results do not support our working hypothesis of an increase in mTORC1 
activity during the differentiation process. Additionally, variability is observed between donors with 
a more pronounced downregulation of the mTORC1 axis observed for donor 3 (Figure 15A), more 
particularly regarding the part of phosphorylated 4EBP1 which is more reduced than in the two other 
donors (Supplementary figure 1C). What’s surprising is that this donor showed the strongest increase 
in NDUFS6 abundance, suggesting a putative mTORC1-dependent regulation of 4EBP1 activity, 
which is apparently not the case.  
 The sequential decreased abundance but reduced phosphorylation of 4EBP1, followed by 
increased abundance and phosphorylation, observed in the differentiating cells, might suggest an 
unchanged global activity with a similar abundance of active 4EBP1 in these cells. Indeed, the 
relevant information regarding eIF4F activity is actually the abundance of the unphosphorylated 
4EBP1, which is the active form of the protein (associated with eIF4E and thereby inhibiting 
translation initiation). The higher abundance of p-4EBP1 observed in undifferentiated cells in the 
early time points thus cannot be interpreted as an indicator of high translational activity as the 4EBP1 
abundance is clearly higher in this experimental condition, leaving many unphosphorylated 4EBP1 
molecules available for eIF4E sequestration. This, together with the unchanged levels of eIF4E, 
 
Figure 16. Functional assessment of eIF4F complex activity and general protein synthesis rate determination. (A) Donor 1 cells were 
collected and cap-binding assay (CBA) was performed on cells in expansion (Exp), cells at day 0 (D0) and differentiating (D) and undifferentiated 
(ND) cells at day 5 (D5) and 15 (D15). 500 µg of proteins were used for the cap binding assay (CBA) and loaded on 6-15% acrylamide gel along 
with 2% of total protein lysates (10 µg), previously saved. eIF4G, eIF4E, GAPDH and 4EBP1 were revealed. (B) SUnSET experiment was 
performed on Exp, Day 0, Diff and Undiff donor 1 cells which underwent a 10-minutes exposure to 5 µg/mL puromycin and were then harvested. 
10 µg of proteins were loaded on 10% acrylamide gel and puromycin and histone H3, the loading control, were revealed. (n=1). (C) Relative 







would suggest no strong differences in eIF4F complex assembly all along the differentiation process. 
In another hand, the reduction in eIF4G abundance in the late time-points would suggest decreased 
eIF4F complex assembly during the differentiation, although it may be that another isoform of the 
scaffold protein ensures translation initiation, the isoform detected here corresponding to eIF4G1. 
The lower abundance of phosphorylated status of 4EBP1 (at least in the early time-points) is 
associated with reduced activation of mTORC1 all along the differentiation complex as supported by 
the reduction in the abundance of p-S6K1 and reduced phosphorylated state of mTOR on S2448. 
Nonetheless, the increased phosphorylation of 4EBP1 at the end of the process in differentiating cells, 
paralleling the increase in its abundance, suggests an increased activity of mTORC1 toward 4EBP1 
at the end of the process, although no increase of mTOR and S6K1 phosphorylation is observed. To 
further assess the functional effect on eIF4F complex assembly of the combined regulation by 
phosphorylation and abundance of 4EBP1, the measurement of eIF4E-4EBP1 binding is necessary 
and this can be measured by a cap binding assay (CBA). This method is based on the specific pull-
down of eIF4E using m7GTP-coated beads, mimicking mRNA cap structure, and subsequent 
detection of its binding partners (Bradley et al., 2002). 
 The CBA was performed on expanding cells and differentiating and undifferentiated cells at day 
0, 5 and 15 (Figure 16A). These time-points were selected to screen the impact of the different 
abundance and phosphorylated state of 4EBP1 on eIF4F complex assembly. First of all, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as a negative control, is not pulled down 
in the CBA, despite its presence in the input (corresponding to total lysate), as expected. In expanding 
cells and cells at day 0, eIF4G binds weakly to eIF4E, as revealed by the weak signal in the pull-
down condition compared with input signal. Further on, eIF4G binding in differentiating cells at day 
5 is stronger than observed in undifferentiated cells whereas eIF4G would be more abundant in 
differentiating cells than in undifferentiated cells, showing opposite results to what was previously 
observed in Figure 14. This discrepancy highlights the previously mentioned high variability between 
donors but also between differentiation processes, as the donor used here corresponds to donor 1, for 
whom a decreased abundance of eIF4G is observed in differentiating cells compared with 
undifferentiated ones (Figure 14A). Secondly, as illustrated in Figure 14, a constant abundance of 
eIF4G is observed in the input for undifferentiated cells, as in the CBA condition (Figure 16A), 
suggesting that eIF4G remains bound to eIF4E with constant abundance in undifferentiated cells. 
However, in the differentiating cells at day 15, eIF4G is even not detected in the CBA, suggesting 
that no functional eIF4F complex is formed in this experimental condition.   
  As observed in Figure 14, the total abundance of eIF4E remains constant during the differentiation 
process with similar levels between both conditions. Similarly, constant pull down of eIF4E 
underlines that no modifications of its binding activity occurs during the differentiation process 
between both conditions. Concerning 4EBP1 total abundance, the previously observed 
downregulation and subsequent upregulation in differentiating cells cannot be observed due to lack 
of resolution and technical problem occurring during the migration in the input gel. Nonetheless, for 
day 15, no upregulation seems to occur in the differentiating condition compared with 
undifferentiated one but no signal for the loading control could be detected, due to technical issues, 
to verify that the differences observed are not due to loading differences. However, regarding its 
association with eIF4E, increased binding of 4EBP1 to eIF4E seems to occur in differentiating cells 
at day 5 and 15 while constant and lower binding occurs in undifferentiated cells. Unexpectedly, at 
day 5 both eIF4G and 4EBP1 are bound to eIF4E in differentiating cells although they normally 
should antagonize each other for eIF4E binding. Comparatively, the fraction of 4EBP1 bound to 
eIF4E, in undifferentiated cells, is reduced at the advantage of eIF4G binding to eIF4E. Importantly, 
as explained for the Figure 14, the only isoform detected by the eIF4G antibody used here is eIF4G1 
and thus no information concerning the other isoforms is provided. Interestingly, a 135 kDa band is 
detected by the antibody only in the differentiating conditions (Figure 16A) and, although the different 
forms of eIF4G1 can be detected by this antibody, even the shortest one is too large to correspond to 




particular experiment was efficient, as shown in Supplementary figure 2, additional replicates are 
required to validate these results.    
  Altogether, these results suggest a decrease in eIF4F complex assembly with increased association 
of 4EBP1 with eIF4E at the expense of eIF4G binding, at least at the end of the differentiation process 
in differentiating cells. At day 5, the picture is much less clear as the increased 4EBP1-eIF4E 
interaction observed in differentiating cells is not compatible with the abundant eIF4G pulled-down 
with m7-GTP-interacting eIF4E. Thus, at least at day 15, this could suggest a reduced global protein 
synthesis in differentiating cells while a maintained assembly of eIF4F complex is observed in 
undifferentiated cells which would thus present constant protein synthesis rate. In order to confirm 
this hypothesis, global protein synthesis rate has been assessed, using the surface sensing of 
translation method (SUnSET) consisting in the exposure of the cells to puromycin, an analogous of 
amino-acyl tRNA which is incorporated in the peptide nascent-chain leading to elongation arrest. 
Afterward, newly synthetized peptides are detected by Western Blott analysis of cell lysates and 
blotting with anti-puromycin antibody. 
 SUnSET experiment was thus conducted all along the differentiation process to further 
characterize precisely relative protein synthesis during 10 minutes (Figure 16B). Negative controls of 
the experiments are shown in Supplementary figure 4, validating the method where no signal can be 
observed in the absence of puromycin treatment and almost no puromycin integration is observed 
upon cycloheximide treatment. Relative protein synthesis in expanding cells and in cells at day 0 is 
higher than in both differentiating and undifferentiated cells. Unexpectedly, quite similar total signal 
is observed for differentiating and undifferentiated cells with a slightly lower signal for differentiating 
cells in the beginning of the process till day 12, while the opposite is observed with a slightly 
increased signal in differentiating cells as compared with undifferentiated counterpart (Figure 16C). 
In addition, protein synthesis seems to slowly decrease in undifferentiated cells with the time. 
However, these results correspond to a single replicate and thus need to be reproduced, also to 
determine if the slight difference observed between differentiating and undifferentiated cells is 
significant or not. The differentiation controls are presented in Supplementary figure 3 and show valid 
differentiation process. 
These results were unexpected regarding the result of the cap-binding assay. Indeed, the increased 
binding of eIF4G to eIF4E in differentiating cells at day 5 and the following loss of eIF4G abundance 
and binding to eIF4E at the end of the process would suggest higher protein synthesis rate at day 5 
which would then decrease at day 15. However, regarding the SUnSET results, the opposite is 
observed. Nonetheless, only eIF4G1 isoform has been addressed and it may be that another one is 
involved in eIF4E binding in differentiating cells. In addition, one element remains unclear: the dual 
binding of both eIF4G and 4EBP1 to eIF4E at day 5 which is unexpected and unexplained along with 
the presence of a 135 kDa band which cannot correspond to another eIF4G1 isoform.   
  Surprisingly, the globally reduced activation of the mTORC1 complex in differentiating cells 
along the differentiation process, underlined by the reduced phosphorylation of mTOR on S2448 and 
of S6K1 phosphorylation, is not corroborated regarding the phosphorylated state of 4EBP1. Indeed, 
although the phosphorylated state of the protein is well reduced in the beginning of the process, 
confirming a reduced mTORC1 activity in the early steps of the process, the increased 
phosphorylation in the end of the differentiation process suggests an increased activity of mTORC1 
toward 4EBP1. Therefore, it appears that mTORC1, which seemed to be the best candidate linking 
translational regulation and mitochondrial remodeling, may not regulate the eIF4E-4EBP1 axis in the 
same way than currently observed as it would maintain a constant pool of active 4EBP1 all along the 
differentiation process. However, this still does not help to explain the discrepancy between the CBA 
and SUnSET results discussed above.  
Nevertheless, in order to complete the characterization of the eIF4E-4EBP1 axis regulation a last 
point had to be addressed: the subcellular localization of both eIF4E and 4EBP1 and eIF4E-specific 




Figure 17. Subcellular localization of eIF4E and 4EBP1 during the differentiation process. Donor 1 cells underwent a differentiation 
process and Exp cells and Diff and Undiff cells at day 0, 5, 12 and 15 were collected, seeded on coverslips and fixed. A green immunofluorescence 










4. Subcellular localization of eIF4E and 4EBP1 and functional characterization of eIF4E 
export function 
 
In order to address the question of a possible regulation of the eIF4E-4EBP1 axis with differential 
subcellular localizations of the two main actors, immunofluorescence analyses and cell fractionation 
followed by protein and RNA analyses were performed. The immunofluorescence experiment was 
performed on expanding cells and undifferentiated and differentiated cells at day 0, 5, 12 and 15. 
Concerning eIF4E localization, the protein was found both in the nucleus and in the cytosol, as 
previously described in other cellular models (Figure 17) (Culjkovic et al., 2005). The signal intensity 
for eIF4E in the differentiating and undifferentiated cells is really faint and does not allow to see any 
differences in the subcellular localization of the protein. In expanding cells, the strong signal for 
eIF4E is diffuse inside the cytosol whereas a similar but weaker signal is observed in cells at day 0. 
Regarding 4EBP1 distribution, the protein is also both found in the nucleus, to a larger extent than 
eIF4E, and in the cytosol in all conditions. A first observation is that the downregulation of 4EBP1 
abundance in differentiating cells seems not clear at day 5 but is more visible at day 12. In addition, 
stronger overall signal of 4EBP1 in differentiating cells compared with their undifferentiated 
counterpart is observed at day 15, confirming the upregulation of 4EBP1 observed by Western Blot 
(Figure 14).  The nuclear to cytoplasm ratio of 4EBP1 observed in expanding cells increases upon 
confluency (day 0) as more 4EBP1 seems to locate in the nucleus. Upon differentiation induction, 
4EBP1 distribution is more diffuse in differentiating cells at day 5 while the nucleus to cytoplasm 
ratio observed in cells at day 0 is maintained in undifferentiated cells till day 15 where a more diffuse 
distribution is observed. At the opposite, the nuclear localization of 4EBP1 increases in cells at day 
12 and this higher nucleus to cytoplasm ratio is maintained at day 15 with stronger overall signal of 
4EBP1 (Figure 17). The negative control antibodies did not reveal any signal, validating these 
observations (Supplementary figure 5). The differentiation process occurred well as shown in 
Supplementary figure 2. 
 In order to biochemically confirm the cell distribution of eIF4E and 4EBP1 observed by 
immunofluorescence, nuclear and cytoplasmic fractionation was performed on expanding cells, 
differentiating and undifferentiated cells at day 0, 5 and 15. The day 12 could not be addressed due 
to lack of cells at this experiment time-point. First, the nuclear marker lamin A/C is predominantly 
detected in total fractions and nuclear fractions, where the abundance is enriched, and is detected to 
a lesser extent in the cytoplasmic fraction of differentiating cells at day 5 and 15, underlining nuclear 
to cytoplasmic contamination. This contamination may be due to an increased fragility and sensitivity 
of the differentiating cells to the hypotonic and thereafter lysis buffers used (associated with the 
typical elongated morphology of differentiating cells at these time-points), resulting in increased 
nuclei lysis. However, for the cytoplasmic marker, LDHA is only detected in the total and 
cytoplasmic fractions of all conditions and is barely detectable in nuclear fractions, indicating that 
the cytoplasmic to nuclear contamination is negligible (Figure 18A).  
eIF4E distribution is also both nuclear and cytoplasmic, confirming the immunofluorescence 
results. In expanding cells, eIF4E signal appears to be weak in all fractions with a little enrichment 
in the cytoplasmic fraction while, in day 0, the protein seems equally enriched in both nuclear and 
cytoplasmic fractions. The difference in the nuclear localization of eIF4E in differentiating cells 
compared with undifferentiated ones is not that clear. Indeed, even if eIF4E seems more enriched in 
the cytoplasmic fraction in differentiating cells, the contamination of the cytoplasmic fraction by 
nuclear proteins makes this result difficult to interpret. In undifferentiated cells however, a slight 
enrichment of the nuclear form of eIF4E is observed at day 5 whereas equal distribution is observed 
at day 15.   
  Concerning 4EBP1 distribution, the protein is mostly found in cytoplasmic fractions, although 
some signal is also detected in the nuclear fractions, except for expanding cells (Figure 18A).  Let’s 







Figure 18. eIF4E and 4EBP1 distribution in subcellular fractions and functional assessment of eIF4E export activity. (A) Donor 3 
cells in expansion and differentiating and undifferentiated cells at day 0 (D0), 5 (D5) and 15 (D15) of differentiation were fractionated and total 
(Tot), nuclear (N) and cytoplasmic (S) fractions were analyzed. After protein extraction on each sample, 10 μg of proteins were loaded on two 6-
15% polyacrylamide gels. Lamin A/C, LDHA, eIF4E and 4E-BP1 were revealed. Lamin A/C corresponds to a nuclear marker and LDHA to a 
cytoplasmic marker, to assess fractionation quality. (B) Quantification of eIF4E signal intensity in the different fractions, presented in A, and 















Figure 18 (following). eIF4E and 4EBP1 distribution in subcellular fractions and functional assessment of eIF4E export activity. (C) 
RNA extraction on each fraction was performed and the relative mRNA abundance of two eIF4E-export function-sensitive (Cyclin D1 and ODC) 
and insensitive (VEGFA and GAPDH) transcripts was assessed using Real-Time PCR. mRNA abundance of each gene is normalized to PPIE 
(Peptidyl-prolyl cis-trans isomerase E) and then expressed relatively to day 0 ratio, for the Tot and N and S fractions. For the S/N ratio the 










found in the nucleus too (Figure 17). In day 0 cells, a stronger signal of nuclear 4EBP1 can be detected 
compared with expanding cells. Once again, due to cross-contamination, the difference in 
differentiating cells cannot be taken into account as most of the 4EBP1 signal is found in the 
cytoplasm fraction at both day 5 and 15 but where an unknown part of the signal probably accounts 
for the nuclear form of 4EBP1 (Figure 18A). Altogether these results globally corroborate with the 
immunofluorescence results. 
 In order to functionally characterize eIF4E export function, the abundance of two eIF4E target 
mRNAs (Cyclin D1 and ODC) and of two negative controls (Vascular endothelial growth factor A 
(VEGFA) and GAPDH) in the different fractions was assessed and their cytoplasmic to nuclear ratio 
was obtained (Figure 18B). In addition, the eIF4E signal detected by Western Blot in the different 
fractions of all conditions has been quantified and represented in Figure 18C, in order to check if the 
eIF4E profile follows the subcellular profile of its target mRNAs. Globally, the general profile of 
eIF4E abundance, with an increase in total abundance at day 5 during the differentiation process, is 
similar between both conditions with nonetheless a stronger decrease in differentiating cells at day 5 
in the nuclear fraction. The reverse profile is observed for Cyclin D1 mRNA which is more abundant 
in the nucleus in differentiating cells at day 5 and yet another scenario is observed for ODC transcript 
distribution which is increasing from day 0 to day 15 in both differentiating and undifferentiated cells. 
Globally, all addressed mRNAs seem to be equally distributed between the two compartments with 
no specific enrichment of eIF4E-sensitive mRNAs in the cytoplasmic fraction compared with the 
nuclear fraction, suggesting an absence of modified eIF4E export function during the differentiation 
process. However, these results do only represent one experiment for both the immunofluorescence 
and the fractionation and thus need replication. In addition, the nuclear to cytoplasmic cross 
contamination issue observed in differentiating cells needs to be fixed and the experiment redone 
before drawing conclusions. 
Altogether these results do not suggest a modification in the export activity of eIF4E during the 
differentiation nor a specific subcellular localization of 4EBP1 and eIF4E in differentiating compared 
to undifferentiated cells. Thus, the regulation of the eIF4E-4EBP1 axis does not seem to be the main 
driver of the putative translational regulation. 
 
5.  Undermining 4EBP1 transcriptional regulation 
 
 In order to understand and link external stimuli corresponding to the different cytokine cocktails 
used and 4EBP1 transcriptional profile, which is correlated at the protein level, the expression of 
several transcription factors was assessed. A first hypothetical model explaining 4EBP1 profile is 
presented in Figure 19. The initial downregulation of 4EBP1 could be associated with the FGF/HGF-
dependent expression of the early growth response 1 (EGR1) transcription factor, a known negative 
regulator of 4EBP1 expression (K. H. Lee et al., 2003; Raucci et al., 2004; Rolli-Derkinderen et al., 
2003), and with the insulin-dependent degradation and cytosolic sequestration of forkhead box O1 
(FOXO1) and FOXO3A, both known to induce 4EBP1 expression (Figure 19A) (Daitoku et al., 2011; 
Puig et al., 2003; Tzivion et al., 2011). Following exposure to the third cytokine cocktail where an 
upregulation of 4EBP1 expression and increased protein abundance is observed, the dexamethasone-
induced expression of REDD1 ensures the restoration of FOXO1/FOXO3A transcriptional activity 
leading to increased 4EBP1 expression (Figure 19B) (Dennis et al., 2014; DeYoung et al., 2008; 
Tzivion et al., 2011; H. Wang et al., 2006). 
 Therefore, in order to test this first hypothesis, the transcriptional profile of both EGR1 and REDD1 
was assessed during the differentiation process (Figure 19C). EGR1 expression appears to be 
extremely fluctuant during the differentiation process without any differences between differentiating 




cells is observed in the beginning of the process compared with differentiating cells which maintain 
lower level of expression till day 12 where a strong (6-fold) induction is observed following 
dexamethasone exposure, as expected. REDD1 expression remains unchanged in undifferentiated 
cells after the 3-fold increase at day 2, with significantly reduced levels compared to differentiating 
cells at day 15, for which REDD1 expression remains higher at day 22. Altogether, these two results 
do not support the potential involvement of EGR1 in 4EBP1 downregulation but they are consistent 
with a REDD1 potential role in the differentiation process, functional assessment of REDD1 activity 
being necessary for complete validation. Always in order to characterize the potential actor involved 
in 4EBP1 downregulation, the expression of the Activating Transcription Factor 4 (ATF4), another 
inducer of 4EBP1 was assessed (Figure 19C) (Yamaguchi et al., 2008). A decrease in ATF4 
expression is observed in differentiating cells where significantly lower (at least at day 3) expression 
remains from day 3 to day 12. ATF4 expression level then increases to reach similar levels than 
observed in undifferentiated cells. The transcriptional profile of ATF4 thus somehow follows 4EBP1 




























Figure 19. Proposed mechanistic hypothesis for 4EBP1 expression profile during the hepatogenic differentiation.       (A) The second 
cytokine cocktail is composed of FGF-2, HGF, nicotinamide and ITS. Upon exposure to this cocktail, several signaling pathways can be activated. 
Indeed, both FGF2 and HGF are known to stimulate the ERK and p38 MAPK pathways (K. H. Lee et al., 2003; Raucci et al., 2004) leading to the 
expression of EGR1 (the transcriptional factor inducing its expression being not known and thus represented by the “?” symbol). EGR1 was 
demonstrated to be a repressor of 4EBP1 expression, which could explain the observed downregulation from day 3 to day 12 (Rolli-Derkinderen 
et al., 2003). In the same time, the insulin induces PI3K pathway and thus AKT activation which is involved in TSC2 inhibition and consequent 
mTORC1 activation. Upon activation mTORC1 phosphorylates and inhibit 4EBP1 (Magner et al., 2013; Showkat et al., 2014). In addition, AKT 
can phosphorylate FOXO transcription factors, mainly FOXO1 and FOXO3A, promoting their ubiquitin-dependent degradation and additional 
sequestration by 14-3-3 proteins preventing their nuclear translocation and transcriptional activity (Daitoku et al., 2011; Tzivion et al., 2011). 
However, FOXO are known to induce 4EBP1 expression (Puig et al., 2003). (B) The third cytokine cocktail is composed of OSM, dexamethasone 
and ITS. The loss of MAPK stimulation would lead to the loss of EGR1-dependent 4EBP1 repression, restoring normal levels of 4EBP1. 
Dexamethasone is known to induce REDD1 expression (H. Wang et al., 2006), which is involved in mTORC1 signaling repression thanks to the 
binding and subsequent sequestration of 14-3-3 proteins (DeYoung et al., 2008). Consequently to the 14-3-3 proteins sequestration, the FOXO, 
transcription factors are free to translocate into the nucleus and to induce 4EBP1 expression. In addition, REDD1 is known to promote PP2A 







1. Hepatogenic differentiation model characterization 
 
Differentiation efficiency is important to address and control each time a differentiation process is 
achieved because of the great variability existing between donor cells, even more important while 
using MSCs which represent highly heterogenous cell populations (Horwitz et al., 2005; Ullah et al., 
2015). Indeed, it was described that in addition to the intra-individual heterogeneity of BM-MSCs 
population, inter-individual differences are observed concerning differentiation potential and growth 
kinetic with donor-dependent features where the sex, age and gender influence several features of 
BM-MSCs. For example, BM-MSCs derived from women are significantly smaller than man-derived 
BM-MSCs and show higher proliferative potential (Siegel et al., 2013). Regarding the variability in 
differentiation efficiency, it becomes clear that individual assessment of differentiation efficiency is 
necessary each time a differentiation process is achieved. Through visualization of the three 
independent differentiation processes presented in Figure 12, heterogeneity between donors is clearly 
apparent where the second donor (Figure 12B) shows, phenotypically and functionally, a higher 
differentiation efficiency with more polygonal-shaped cells at the end of the process associated with 
numerous PAS-positive cells. 
The morphological changes observed during the differentiation process are the result of the action 
of cytokines found in the differentiation media. HGF, found in the second cytokine cocktail ensuring 
hepatic differentiation, is known to induce actin cytoskeleton rearrangement, in part through the 
regulation of Asef-IQGAP1 complex regulating the Cdc42-Rac1 complex controlling actin 
polymerization (Rodrigues et al., 2010; Tian et al., 2015). Similarly, hepatic maturation, ensured by 
the third cytokine cocktail, involves OSM, known to reorganize actin cytoskeleton through Protein 
Threonin Kinase 2 B (PTKB2)-Paxillin activity. In addition, the glycogen accumulation observed in 
differentiated cells is the result of the glycogen synthase activity whose expression and activity are 
both upregulated by the synergetic action of dexamethasone and insulin (Fleig et al., 1985; Huang et 
al., 2000).  
The late induction of the major circulating serine protease inhibitor α-1-antitrypsin from day 12 
onwards suggests an effect of the third cytokine cocktail containing OSM, described to induce its 
expression through signal transducer and activator of transcription 3 (STAT3) activity and binding to 
an OSM responsive element in a 3’ enhancer of α1AT gene (Morgan et al., 2002). In addition, OSM 
is also described to induce the expression of TDO2 (Teratani et al., 2005). Indeed, STAT3 would 
potentiate the transcriptional activity of HNF1α for the expression of liver specific transcripts such 
as α1AT but also TDO2 (Leu et al., 2001). The TDO2 transcript encodes for an enzyme involved in 
the early steps of the Kynurenine pathway and thus in tryptophan catabolism (Jones et al., 2013). The 
strong increase in differentiating cells, up to day 12, is expected but the brutal decrease is not 
explained. Nonetheless, the TDO2 transcript levels remain higher in differentiating cells than in 
undifferentiated cells at the end of the process, supporting an efficient differentiation process. TDO2 
expression is essentially restricted to the liver and normally increases at the end of hepatogenic 
differentiation process and during hepatic maturation (Banas et al., 2007). Insulin signaling is also 
described to be involved in the induction of both α1AT and TDO2 through induction of both HNF1α 
and HNF4α, two known master regulators of numerous hepatic genes (Magner et al., 2013). HGF, 
FGF and dexamethasone, mainly, are also upstream regulators controlling HNF4 transcription factors 
expression (Michalopoulos et al., 2003).   
  The transcription factor TBX3 is a known regulator of several developmental processes such as 
limb formation, heart, liver and mammary gland development (Washkowitz et al., 2012; Weidgang 
et al., 2013). During embryonic development, TBX3 is first involved in the autoregulatory-loop 














Figure 19 (following). Proposed mechanistic hypothesis for 4EBP1 expression profile during the hepatogenic differentiation.   (C) 
Expression of EGR1, REDD1 and ATF4 in Diff and Undiff cells along the differentiation process, assessed by Real-Time PCR. mRNA abundance 
of each gene is normalized to PPIE (Peptidyl-prolyl cis-trans isomerase E) and then expressed relatively to day 0 ratio. Data are presented as mean 















(Weidgang et al., 2013). During liver development (Figure 3), TBX3 directs hepatocyte and 
cholangiocyte differentiation. It is thus expressed in hepatoblasts and disappear after lineage 
commitment (Gordillo et al., 2015) as it is illustrated by its increased expression during the hepatic 
differentiation step and subsequent reduced expression during hepatic maturation. In addition, TBX3 
is a known downstream effector of both Wnt and FGF signaling  (Washkowitz et al., 2012), the latter 
being present from day 2 to day 12, correlating with TBX3 increased expression in differentiating 
cells. Thus, the used in vitro differentiation protocol does induce hepatic differentiation and 
subsequent maturation with the triggering of master regulators involved in cell fate commitment and 
cell differentiation at the appropriate time.   
  The significantly reduced SOX9 expression in differentiated cells at the end of the process further 
confirms previous observations (Wanet et al., 2014) and confirms the occurrence of a differentiation 
process. SOX9 is involved in the maintenance of the cells in an undifferentiated state (Kawaguchi, 
2013). Its expression is indeed comparable between undifferentiated cells and expanding cells but 
also between differentiated and expanding cells, which is not expected. Despite the absence of 
significant differences between differentiated cells and expanding cells, previously described, a 
significant decrease is observed compared to day 0 showing reduced pluripotency compared to the 
cells just prior entry in differentiation program. This absence of significant difference between 
expanding cells and differentiated cells could be explained by the variability between donors for the 
EXP condition at least. In addition, SOX9 is a master regulator of testis determination (Bhandari et 
al., 2012), marker of pancreas and liver (cholangiocytes) duct cells (Kawaguchi, 2013) and a marker 
of chondrogenic differentiation (Siegel et al., 2013), thus confirming the specificity of the used 
hepatogenic differentiation protocol. Interestingly, following results of the transcriptomic analysis 
performed on this model, the expression of the cholangiocyte marker Keratin 7 (KRT7) is strongly 
downregulated at days 3 and 5 in differentiating cells compared with expanding and undifferentiated 
cells (Table 1), confirming, with SOX9 downregulation, hepatic specification and underlying activity 
of TBX3.  
 Altogether these results confirm that a differentiation process was indeed initiated in the three 
donors, despite variability in differentiation efficiency due to donor-dependent responsiveness to the 
differentiation process. The used protocol mimics the molecular mechanisms observed during in vivo 
liver development with a first acquirement of hepatoblast-like cells directed to hepatocyte 
differentiation, followed by incomplete maturation. 
Before addressing the question of translational regulation, we wanted to verify that a mitochondrial 
remodeling does occur during the differentiation process. The nuclear-encoded ATP5A and ATP5B 
abundance normally correlates with mitochondrial abundance and was described to increase during 
the differentiation process, associated with the mitochondrial remodeling (Wanet et al., 2014). 
Therefore, the results observed for ATP5A and ATP5B abundance with no differences between 
differentiating and undifferentiated cells were not expected. NDUFS6, a mitochondrial protein 
necessary for complex I assembly, is a known target translationally upregulated by mTORC1 (Morita 
et al., 2013; Stroud et al., 2016). Thus, the increase in NDUFS6 abundance but not in the abundance 
of the two other mitochondrial proteins, could underline that a translational regulation involving 
mTORC1 axis indeed occurs. Although no significant differences could be detected for NDUFS6 
abundance between differentiating and undifferentiated cells, a consistent increase of NDUFS6 
abundance is observed in differentiating cells in each donor cells, suggesting that the analysis of 
additional replicates would probably allow to reach significance. 
In addition, the analysis of mtDNA content, used as a marker of mitochondria biomass, reveals an 
increase in differentiating cells, although this increase does not occur at the same time-point for the 
two donors, highlighting donor-dependent variability. The correlated increase observed in mtDNA 
and NDUFS6 abundance strengthen the hypothesis of mTORC1 activity, known to ensure 
mitochondrial biogenesis through the regulation of 4EBP1 activity. mTORC1 indeed promotes 







Figure 20.  eIF4GI encodes different isoforms (adapted from, Coldwell & Morley, 2006). (A) Diagrammatic representation of the 
eIF4GI gene locus, showing the locations of the three promoters, designated α, β, and γ. Coding exons are shown in gray, and noncoding exons 
are shown in black.  (B) Diagrammatic representation of the eIF4GI mRNAs showing alternative splice variants generated from the different 
promoters. (C) Schematic representation of the eIF4G1 protein. This figure shows the sites of alternative translation initiation, binding sites of 













transcripts like NDUFS6 (Morita et al., 2013, reviewed in, Morita et al., 2015). In addition, mTORC1 
would also promotes mtDNA replication as the inhibition of its activity results in a 40% decrease of 
mtDNA content in MEF (Morita et al., 2013). The putative involvement of mTORC1 in the regulation 
of the eIF4E-4EBP1 axis during the hepatogenic differentiation process is further supported by the 
strong upregulation of PPARγ in the early stages of the process (Table 1), as mTORC1 has been 
described to drive adipogenesis through the induction of PPARγ (H. H. Zhang et al., 2009). Moreover, 
mTOR-dependent 4E-BP1 hyperphosphorylation is involved in the increased protein synthesis 
associated with murine embryonic stem cell differentiation (Sampath et al., 2008). Interestingly, 
insulin, contained in the second and third cytokine cocktails, is a known activator of PI3K-mTORC1 
pathway and could explain a potential activation of this pathway leading to mitochondrial biogenesis 
(Roux & Topisirovic, 2012; Showkat et al., 2014).   
Altogether, these results globally support that a mitochondrial remodeling occurs during the 
differentiation process, as it has been previously characterized in this model of hepatogenic 
differentiation (Wanet et al., 2014). Indeed, despite variability between donors, the increased 
abundance of some mitochondrial proteins (NDUFS6 mainly) and of mtDNA content confirm a 
mitochondrial biogenesis. The question of the involvement of a translational regulation as part of the 
mitochondrial remodeling regulation can thus be addressed as the increase in NDUFS6 abundance 
suggests mTORC1 involvement. 
 




 In order to characterize a putative translational regulation, the abundance of several eIF4F 
components and actors of the eIF4E-4EBP1 axis has been first addressed. Regarding the abundance 
of the scaffold protein eIF4G1, its decreased abundance in differentiating cells would suggest a 
reduced canonical cap-dependent translation as less eIF4G1 molecules are available for eIF4E 
association, whose abundance is maintained constant during the differentiation. However, three 
different isoforms of eIF4G exist, eIF4G1 being the most studied and the sole isoform investigated 
in this work (Bradley et al., 2002). Additionally, several short isoforms of eIF4G1 exist, as illustrated 
in Figure 20 (Bradley et al., 2002; Coldwell & Morley, 2006; Jackson et al., 2010). Indeed, through 
the activity of three different promoters (α, β and γ), alternative splicing and alternative translation 
initiation sites, the eIF4GI gene encodes seven different eIF4G1 transcripts (Byrd et al., 2002; 
Coldwell & Morley, 2006). Five transcripts are produced through alternative splicing from the α 
promoter whereas two others are produced by the β and γ promoters activity. The transcripts deriving 
from the α and β promoters ensure the production of five polypeptides showing different N-terminal 
sequence length but presenting similar translational activity, with higher potency for the longest form. 
The two longer isoforms are the most abundant ones in human and can be observed on Figure 14A 
for some experimental conditions but not for all of them because of poor resolution. A sixth and 
shorter polypeptide is produced by the γ promoter and show differential activity due to the absence 
of the PABP binding domain in its N-terminal domain, reducing its ability to promote efficient 
translation initiation (Coldwell & Morley, 2006). An additional layer of regulation for eIF4G1 
expression corresponds to the presence of IRES in the transcript and of one uORF in the 5’UTR of 
the transcript, reducing the translation of the downstream ORF (Byrd et al., 2002). Thus, eIF4G1 
expression control shows a complex regulation at both the transcriptional and translational levels. 
Additionally, a cleaved form of eIF4G1, called p100 and resulting from viral proteinase activity, is 
also able to ensure translation even if unable to bind to eIF4E. Indeed, p100 is known to specifically 
ensure the translation of a subset of mRNAs by delivering the 40S ribosomal subunit to the 5’UTR 




eIF4G1 leading to the formation of shorter fragments lacking PABP binding domain but still able to 
bind to eIF4E, therefore acting as translational inhibitors (Marissen et al., 2000; Marissen & Lloyd, 
1998).  
  Two other eIF4G isoforms also exist and could be involved in translation initiation during the 
differentiation process. The ubiquitous isoform eIF4G2 (also known as Death Associated Protein 5 
(DAP5), NAT1 or p97) could be a good candidate as it is known to be involved in the translational 
regulation driving megakaryocyte differentiation, this isoform being selectively recruited for eIF4F 
complex assembly in the early stage of the differentiation process (Caron et al., 2004). This specific 
recruitment of eIF4G2 follows thrombopoietin signaling and leads to eIF4E S209 phosphorylation 
by the associated MNK1 (Caron et al., 2004; Jackson et al., 2010). In addition, ERK 1/2 and p38 
MAPK pathways synergic activation is necessary to achieve this phosphorylation associated with 
reduced eIF4E-4EBP1 association and thus increased protein synthesis (Caron et al., 2004). 
Interestingly, no modifications of eIF4G1 and eIF4G2 expression is observed with this selective 
association of eIF4G2 with eIF4E, as observed in our case (Table 1). Nonetheless, eIF4G2 doesn’t 
contain an eIF4E binding domain as well as a PABP binding domain while containing a MNK1, 
eIF4A and eIF3 interacting domains. It has been first proposed to act as a negative regulator of the 
eIF4F complex assembly, which can bind eIF4A and eIF3 and could sequester MNK1 and the 43S 
complex, preventing eIF4E-dependent cap translation (Pyronnet et al., 1999). Indeed, eIF4G2 seems 
to essentially ensure cap-independent translation with the specific translation of IRES-containing 
mRNA, in association with eIF2β and eIF4A1 (Liberman et al., 2015). Among the targeted mRNA, 
the anti-apoptotic protein Bcl2 was the first specific eIF4G2-target described.  Among other targets, 
the scaffold protein also ensures its own IRES-dependent translation, providing an auto-regulatory 
loop supporting continuous cap-independent translation in contexts of impaired cap-dependent 
translation (Liberman et al., 2015; Yoffe et al., 2016). Given this and the results obtained by Caron 
et al., where a specific pull-down of eIF4E and subsequent revelation of eIF4G2 revealed the 
association of these two proteins, the question of a potential indirect interaction between eIF4E and 
eIF4G2 is the more probable hypothesis and still need to be addressed.  
  Finally, the third eIF4G paralog, eIF4G3, is less known and has been described, in mouse, to be 
involved in the translational regulation of the chaperone HSPA2 necessary for cyclin-dependent 
kinase 1 (CDK1) activity involved in meiotic prophase regulation. This isoform would ensure 
translational regulation in testis necessary for spermatogenesis and its deficiency is linked to male 
infertility in mouse (Sun et al., 2010). Although eIF4G3 isoform is less relevant in our case, eIF4G2 
is a good candidate for a possible involvement in the putative and suspected translational regulation 




The mRNA and protein levels of 4EBP1, the main regulator of the eIF4F complex, were addressed. 
The robust downregulation of 4EBP1 expression, in differentiating compared with undifferentiated 
cells, initially revealed by the transcriptomic analysis performed in the early stage of the 
differentiation process (Table 1), was confirmed by qPCR analysis, despite the absence of significant 
differences (Figure 14A). This decreased expression is verified at the protein level and thus could 
suggest a decrease in 4EBP1 binding activity and relieve of the eIF4F complex repression, supporting 
increased cap-dependent translation. Further on, the upregulation of 4EBP1 observed during the 
hepatic maturation step, suggests that the reverse phenomenon happens in the end of the 
differentiation process. Due to its role in translational regulation and promotion of mitochondrial and 
ribosomal-associated transcript translation (Morita et al., 2013; Tahmasebi et al., 2016), the putative 
involvement of the eIF4E-4EBP1 axis in the mitochondrial remodeling is supported by this data. In 
addition, 4EBP1 is also involved in the control of YY2 specific translation, ensuring pluripotency 
markers expression repression and involved in the upregulation of several mitochondrial genes 




translational control of the balance between stemness maintenance and differentiation on one hand 
and in the control of mitochondria abundance and activity on the other hand, it would not be surprising 
to find an involvement of this axis in the mitochondrial remodeling occurring during this 
differentiation process.   
  The unchanged abundance of eIF4E, correlated with the fluctuant profile of 4EBP1, supports an 
early increase in cap-dependent translation during the first steps of the differentiation process while 
the opposite interpretation can be drawn for the end of the process with reduced eIF4F complex 
assembly and thus translation. However, before drawing any conclusions, the functional regulation 
of the eIF4E-4EBP1 axis by post-translational modifications needed to be addressed. 
 
3. Another purpose for the mTORC1-dependent regulation of the eIF4E-4EBP1 axis 
 
The unchanged phosphorylated state of eIF4E all along the differentiation process, despite a 
decrease in eIF4G1 abundance is unexpected since eIF4G1 is necessary for the recruitment of MNK1 
responsible for the phosphorylation of the eIF4E bound to the same eIF4G1 molecule (Jackson et al., 
2010; Pyronnet et al., 1999). However, the two other eIF4G1 isoforms, namely eIF4G2 and eIF4G3, 
also possess an MNK1 binding domain and could thus ensure MNK1-dependent phosphorylation of 
eIF4E on S209 (Pyronnet et al., 1999). Whereas, eIF4G3 is a functional homolog of eIF4G1 able to 
ensure cap-dependent translation in case of viral- dependent cleavage of eIF4G1 (Gradi et al., 1998), 
eIF4G2 does not directly bind eIF4E and would thus not be involved in its phosphorylation (Pyronnet 
et al., 1999). However, as discussed above, a yet unidentified intermediate interactor could be 
involved in the bridge between eIF4E and eIF4G2, thereby ensuring MNK1-dependent eIF4E 
phosphorylation (Caron et al., 2004).  As a consequence, the maintained phosphorylation state of 
eIF4E suggests a maintained translational function as it is required for UBC9-dependent sumoylation 
and enhancement of eIF4E binding to eIF4G, at the expense of 4EBP1 binding (Xu et al., 2010). 
However, the cap-binding assay (Figure 16A) reveals that eIF4E association with 4EBP1 is not 
decreased in differentiating cells, and is even slightly increased, which suggests reduced eIF4F 
complex assembly. However, the question of a potential eIF4G3 binding could be addressed to check 
if the eIF4F complex assembly is maintained, in agreement with only slight differences in global 
protein synthesis rate observed in differentiating cells all along the process.   
Nonetheless, S209 phosphorylation is also associated with increased eIF4E affinity for the cap-
moiety, in synergy with Chip-dependent mono-ubiquitination of eIF4E on the K159 residue. This 
mono-ubiquitination is involved in the proteasome-dependent degradation of eIF4E which is reduced 
upon 4EBP1 binding to eIF4E. This would suggest that 4EBP1 binding could protect eIF4E from 
degradation and could remain associated in ternary complexes with eIF4E and bound mRNAs under 
low levels of mTOR-induced phosphorylation an inhibition of 4EBP1 (Murata & Shimotohno, 2006), 
as observed in differentiating cells during the first part of the differentiation process. This poised 
translational status of the cells allows for a rapid increase in translation upon increased 
phosphorylation of 4EBP1, as observed during the hepatic maturation step, where the eIF4E-bound 
mRNAs can be rapidly translated. Due to their mTORC1-sensitivity, TOP-containing mRNAs, such 
as several mitochondrial transcripts,  would be the first translated through the targeted and spatially 
restricted 4EBP1 phosphorylation, targeting 4EBP1 removal from these eIF4E-associated TOP 
mRNAs (Hong et al., 2017). However, in order to confirm this hypothesis, the maintenance and 
increased assembly of the eIF4F complex at the end of the process, when increased phosphorylation 
of 4EBP1 is observed, should first be verified by addressing the question of eIF4G3 binding to eIF4E. 
As mentioned, a reduced phosphorylation of 4EBP1 is observed during the hepatic differentiation 
step suggesting a reduced activity of mTORC1 during the first part of the differentiation process 
(Showkat et al., 2014). However, in order to assess total mTORC1 activity the phosphorylation levels 




total activity, both the proportion of the phosphorylated form of its two main targets (S6K and 4EBP1) 
and the total phosphorylation of mTOR on S2448, associated with active mTORC1-containing 
mTOR, were addressed (Figure 15). Considering all three parameters, mTORC1 total activity seems 
to be globally reduced in differentiating cells during the first part of the differentiation process with 
the reduced phosphorylation of mTOR on S2448 correlating with reduced phosphorylation of its 
downstream targets. In addition, a reduced abundance of both targets is also observed in 
differentiating cells compared with undifferentiated cells, resulting, for S6K1, in a constant 
proportion of phosphorylated S6K1 (similar and constant phosphorylated/total form ratio between 
the two experimental conditions) all along the differentiation process. 
 Regarding mTORC1 activity toward 4EBP1, we hypothesize that the modification of 4EBP1 
abundance is compensated by modifications in the phosphorylated fraction of this protein to maintain 
a constant number of active 4EBP1 molecules (i.e. a constant number of unphosphorylated 4EBP1 
molecules) in differentiating cells. In order to maintain this constant pool of active 4EBP1, mTORC1 
activity is reduced in the beginning of the process characterized by a low 4EBP1 abundance. 
Afterwards, the upregulation in 4EBP1 abundance requires an increased activity of mTORC1 to 
phosphorylate much more 4EBP1 molecules in order to maintain similar levels of active 4EBP1. 
Thus, together with the constant level of eIF4E during the differentiation process, this would suggest 
constant level of eIF4E-bound 4EBP1 complexes in differentiating cells all along the differentiation 
process, which is confirmed by the CBA (Figure 16A). Similarly, in undifferentiated cells, the 
abundance and phosphorylated state of 4EBP1 is maintained with a constant activation of mTORC1 
leading to reduced levels of 4EBP1 bound to eIF4E compared with differentiating cells (Figure 16A). 
According to this hypothesis, this precise number of active 4EBP1 would ensure a fine tuning of the 
eIF4F complex assembly.  
  Altogether these results support a reduced activity of mTORC1 in differentiating cells, mainly in 
the beginning of the process. This was unexpected regarding the specific increased abundance, 
already in the beginning of the process, of the mitochondrial protein NDUFS6, one of the 
translationally upregulated targets of mTORC1 and the known role of mTORC1 connecting 
mitochondria biogenesis and translational regulation (Morita et al., 2013). Indeed, despite a low 
increase in mTORC1 activity toward 4EBP1 at the end of the process, the maintained binding of 
4EBP1 to eIF4E and the absence of a clear difference in relative protein synthesis between 
differentiating and undifferentiated cells does not support a clear involvement of the mTORC1-
eIF4E-4EBP1 axis in a putative translational regulation supporting the mitochondrial remodeling 
observed during the differentiation process. 
Nonetheless, one major point remains unexplained. Regarding relative protein synthesis, while the 
main driver of protein synthesis in undifferentiated cells can be easily explained by the mTORC1-
dependent phosphorylation of 4EBP1 and subsequent reduced binding of 4EBP1 to eIF4E which 
allows eIF4G binding and eIF4F complex formation, one question remains for differentiating cells: 
why is there a maintained translational rate in those cells where a constant inhibition of the eIF4F 
complex assembly seems to occur, suggesting a complete shutdown of translation during the 
differentiation process (Figure 16)?  In addition, the dual association of eIF4E with both eIF4G and 
4EBP1 in differentiating cells at day 5 is unexpected and would suggest a normally higher 
translational rate compared with these cells at day 15, where only 4EBP1 is detected in association 
with eIF4E at the expense of eIF4G, which abundance is additionally reduced. However, the opposite 
is observed.   
  A first explanation would be that the eIF4F complex could be formed by another isoform of eIF4G 
such as eIF4G3, as discussed previously. In addition, cleaved forms of eIF4G1, by viral proteinase 
but also by caspases can generate either translationally functional or inhibitory fragments of eIF4G1 
(reviewed in, Prévôt et al., 2003) and this could correspond to the unidentified 135 kDa band pulled-
down with eIF4E and observed in differentiating cells at day 5 and 15 (Figure 16A). Although no viral 




the differentiation process, preliminary data suggested a potential activation of caspase 3 in 
differentiating cells at day 5 compared with undifferentiated cells for which no such activation was 
observed (Wanet et al., 2017). The eIF4G1 fragments generated by caspase 3 present, for the longest 
of them, a size of 120 kDa (Marissen & Lloyd, 1998) which could then correspond to the 
uncharacterized band. Additionally, these fragments prevent translation initiation since they bind 
eIF4E but do not contain a PABP binding domain preventing eIF4F complex assembly (Marissen et 
al., 2000; Marissen & Lloyd, 1998).  
  Another hypothesis to explain these discrepancies could be that the eIF4E-4EBP1 axis would be 
regulated at the level of subcellular localization of both actors, targeting the export activity of eIF4E. 
However, following the immunofluorescence and fractionation results, it does not seem that this axis 
is specifically regulated in this case, as the export of two eIF4E-sensitive mRNAs does not seem to 
be modified in differentiating cells over the time and compared with undifferentiated cells. In 
addition, no clear differences in eIF4E and 4EBP1 localization can be observed between the two 
conditions: an increase in eIF4E and 4EBP1 nuclear localization is observed in both conditions upon 
confluency reaching (already at day 0), compared with expanding cells. This could be explained by 
the fact that expanding cells are actively dividing compared with confluent cells and thus present a 
higher protein synthesis rate, as observed in the SUnSET experiment, and thus eIF4E is more 
associated with the translational machinery in the cytoplasm and 4EBP1 is more inhibited, supported 
by the increased mTORC1 signaling observed in expanding cells. Although additional replicates are 
necessary to confirm these results as well as more functional assessment of eIF4E export activity, the 
regulation of the localization of both eIF4E and 4EBP1 would not be the main driver of eIF4E-4EBP1 
axis regulation and can’t help to explain by itself the unexpected results obtained so far. One way to 
more functionally address eIF4E function would be to assess its binding activity to target mRNAs in 
the nucleus of differentiating cells and during the differentiation, using RNA immunoprecipitation 
and subsequent RNA sequencing.  
  Still another hypothesis could involve the eIF2α axis as the main driver of the putative translational 
regulation, well-known to ensure translation initiation repression in case of several stresses (Holcik 
& Sonenberg, 2005). In addition this regulatory axis was one of the main candidate shown to be 
strongly and robustly downregulated following the transcriptomic analysis performed in the early 
stage of the differentiation process (Wanet et al., 2017). However, according to preliminary data, it 
does not appear that this axis plays a specific role in translation initiation regulation during the 
differentiation process (unshown data).  
The last and most relevant hypothesis to our opinion would concern a transition, in differentiating 
cells, in the mode of translation. Indeed, upon differentiation induction, cells would change from a 
cap-dependent translation to a cap-independent and IRES-based translation. A first argument for this 
hypothesis, already mentioned, concerns the eIF4G2-dependent translational regulation observed 
during megakaryocyte differentiation (Caron et al., 2004). As explained before, eIF4G2 is 
preferentially recruited to eIF4E and would ensure its phosphorylation and enhancement of 
translation. However, subsequent studies showed that this isoform of eIF4G strictly ensures IRES-
based translation in a rabbit reticulocyte lysate (Liberman et al., 2015). Interestingly, another 
experiment showed the requirement of IRES-dependent translation in megakaryocyte differentiation 
(Grech & von Lindern, 2012). This could suggest that the essential role of eIF4G2 during 
megakaryocyte differentiation determined by Caron et al. could be due in part to its IRES-based 
translational function in addition to a potential but not essential role in eIF4E-phosphorylation, but 
this needs experimental confirmation. In addition, eIF4G2 requires eIF2β and eIF4A1 association to 
further ensure its cap-independent translation where active helicase activity of eIF4A1 is required 
(Liberman et al., 2015).   
  Another argument comes from in vivo experiments: late gestational fetal rat hepatocytes are 
resistant to rapamycin treatment, whereas adult counterparts are sensitive to that treatment (Boylan 
et al., 2015; Gruppuso et al., 2008). Hepatocyte maturation would thus not be affected by mTORC1 




mRNAs in the polysomal fraction upon mTORC1 inhibition by rapamycin in fetal hepatocytes 
(Gruppuso et al., 2008). Although the mechanism underlying this rapamycin resistance remains to be 
elucidated, it could depend on a specific modification of the eIF4F complex as eIF4A1 is highly 
abundant in polysomal fractions (Boylan et al., 2015; Gruppuso et al., 2008).  Thus, this rapamycin 
resistance in fetal hepatocyte might be due to an eIF4G2-dependent/cap-independent translation 
(Boylan et al., 2015; Gruppuso et al., 2008). 
  Last but not least, a recent study showed the involvement of eIF4G2 in the differentiation 
regulation and priming of hESCs through the eIF4G2-based cap-independent translational regulation 
of pluripotency markers and mitochondrial transcripts (Yoffe et al., 2016). The previously shown 
lethality of eIF4G2 depletion in mouse would be explained by its essential role in the control of hESC 
differentiation which is impaired upon eIF4G2 depletion. The scaffold protein ensures the 
translational downregulation of pluripotency markers such as Nanog or Oct4 and promotes the 
translation of differentiation markers in response to extracellular stimuli. In addition, and most 
importantly, the differentiation impairment observed in hESC depleted from eIF4G2 would be due to 
impaired mitochondrial remodeling required for the metabolic transition naturally occurring upon 
ESC differentiation. Indeed, the loss of eIF4G2, which does not affect the translation of TOP-
containing mRNA in MEF (Thoreen et al., 2012), leads to a shift of several mitochondrial transcripts 
(assembly factors, OXPHOS components,…) and translation-related transcripts (essentially 
ribosomal proteins) from polysomes to monosomes (Yoffe et al., 2016). Therefore, the role of eIF4G2 
in the hepatogenic differentiation should be addressed regarding its essential developmental role and 
putative role in fetal hepatocytes.  
Regarding the results presented here, a transition from a cap-dependent to cap-independent 
translation in differentiating cells could correlate with a decreased mTORC1 signaling which is no 
more necessary to support protein synthesis but would mainly control and maintain a constant level 
of active 4EBP1. This fine-tuning of eIF4F complex formation, based on the association of eIF4E 
with another scaffold protein, such as eIF4G3, could be necessary to prevent the sequestration of eIF3 
and eIF4A1 by these eIF4F complex, therefore promoting the maintenance of their association with 
eIF4G2, ensuring the cap-independent translation of mitochondrial transcripts, among others. In 
addition, a caspase 3-dependent generation of cleaved inhibitory fragment of eIF4G1 could also be 
involved in the required eIF4F complex assembly inhibition. Nonetheless, the constant 
phosphorylation of eIF4E and the increased global protein synthesis observed in the differentiating 
cells during the hepatocyte maturation step could highlight a possible maintained formation of eIF4F 
complexes with an increase in their assembly at the end of the process. In order to address this 
question, cap-binding assays and revelation of eIF4G3 all along the differentiation process should be 
performed. To further check if a constant number of unphosphorylated 4EBP1 is indeed required to 
fine tune the differentiation process and check if thus mTORC1 activity is essential for the 
differentiation, 4EBP1 point mutation with replacement of mTORC1 target amino acid (mainly 
T37/46) by alanine could be done, rendering these mutants resistant to mTORC1-directed 
phosphorylation. 
Nonetheless, the transition from a cap-dependent to cap-independent translation would result in 
specific modifications of the translatome whereas to functionally address such translational 
regulation, polysome-enriched transcripts in differentiating cells compared with undifferentiated ones 
should be analyzed using different unbiaised methods. Polysome profiling on the early stage of the 
hepatogenic differentiation is under investigation in the lab and will characterize the existence of the 
putative translational regulation of the mitochondrial remodeling. Other high-throughput methods 
could be performed in order to functionally characterize the cell translatome such as ribosome 
profiling or even puromycin-associated nascent chain proteomics (PUNCH-P) to have a protein 




Figure 21. Proposed model for 4EBP1 transcriptional regulation. (A) Upon exposure to the first and second cytokine cocktails (the cytokines 
are numerated following their presence in the first (1), second (2) or third (3) cocktail), the same actors as those involved in the first hypothesis 
(Figure ) are maintained with the sole difference concerning the downstream effector of the p38 and ERK MAPK pathways leading to the induction 
of C/EBPβ, a repressor of ATF4 which normally drives 4EBP1 expression. Additionally, the EGFR activation due to EGF exposure, present in the 
first cytokine cocktail, also targets MAPK activation. Nicotinamide is converted into NAD+ in the cells, promoting Sirtuin 1 activity which targets 
the deacetylation of FOXO1, associated with reduced transcriptional activity. (B) Following exposure to the third cytokine cocktail, the MAPK-
dependent induction of C/EBPβ is lost, while the repressive signaling of insulin remains, leading to ATF4 expression which, together with FOXO 






4. Literature-driven model of 4EBP1 transcriptional regulation 
 
In another context, the putative transcriptional network controlling 4EBP1 expression led to a first 
hypothesis was explored, and depicted in Figure 19. Although the experimental results obtained for 
REDD1 expression are in accordance with the hypothesis explaining 4EBP1 upregulation, those 
obtained for EGR1 expression did not confirm the proposed hypothesis for the downregulation of 
4EBP1. Therefore, we propose a second hypothesis with ATF4 as one of the transcription factors 
involved in the control of 4EBP1 profile during the differentiation (Figure 21). This transcription 
factor induces several genes involved in amino acid and nucleotide synthesis, among others. ATF4 is 
also an inducer of 4EBP1 expression under endoplasmic reticulum stress (Yamaguchi et al., 2008). 
Interestingly, ATF4 expression is itself repressed by the hepatic transcription factor C/EBPβ (Dey et 
al., 2012), which expression is induced by EGF (Li et al., 2014), FGF-1 (Rajesh Raju et al., 2014) 
and HGF (Shen et al., 1997). At the opposite, the insulin repress C/EBPβ expression (Bosch et al., 
1995). Thus, following the exposure to the first and second cytokine cocktails, ATF4 expression is 
globally repressed by C/EBPβ (Figure 21A), while the absence of these inducers in the third cytokine 
cocktail but not of insulin, which represses C/EBPβ, leads to the repression of C/EBPβ and 
consequent restoration of ATF4 expression (Figure 21B). The experimental data shows that ATF4 
expression does follow 4EBP1 expression and thus corroborates the proposed model. Additionally, 
4E-BP1 expression is also induced by HIF1α (Azar et al., 2013), a transcription factor strongly 
downregulated in the differentiation process (Table 1) and a potent candidate linking mitochondrial 
remodeling and hepatogenic differentiation (Wanet et al., 2017).  
In addition, the nicotinamide found in the second cytokine cocktail leads to the final production of 
NAD+, an important cofactor for redox reaction, involved in several metabolic pathways such as the 
tricarboxylic acid cycle (TCA), glycolysis, pentose phosphate pathway, β-oxidation of fatty acids, 
among others. Interestingly, NAD+ is also a co-substrate used by Sirtuins, a major family of 
deacetylase, involved in the regulation of numerous cell processes such as metabolic or epigenetic 
processes taking part to stem cell maintenance and differentiation (Figure 2) (reviewed in, Rodriguez 
et al., 2013; Lisowski et al., 2018). Sirtuin 1, the main cytoplasmic and nuclear sirtuin is known to 
deacetylate FOXO1, leading to its reduced transcriptional activity (Daitoku et al., 2011). The 
provided nicotinamide during the hepatic differentiation step would thus promote sirtuin activity and 
additional repression of FOXO1 function which is relieved upon exposure to the third cytokine 
cocktail which does not contain nicotinamide (Figure 21).   
   
In order to further confirm the new hypothesis, the expression of CEBP/β during the differentiation 
process should be assessed. In another hand, to validate the proposed mechanism for REDD1-
dependent upregulation of 4EBP1, immunoprecipitation of FOXO1 and FOXO3A could be 
performed in order to check their association with 14-3-3 proteins. A colocalization study could also 
be performed to check the cytosolic versus nuclear localization of these factors and their associated 
inhibitor. In addition, functional study of FOXO1 and FOXO3A could also be performed in order to 
characterize their transcriptional activity such as chromatin immuno-precipitation experiment with 
subsequent sequencing. 
The proposed model of transcriptional regulation for 4EBP1 expression thus involves master 












The differentiation model used in this work can be handled and used to study developmental 
processes, that require further in vivo validations (Wanet et al., 2017). However, due to the intrinsic 
nature of the cells, and more precisely, of the MSC populations used, large inter- and intra-individual 
variability is observed, requiring a higher number of replicates to draw representative and relevant 
conclusions. Nonetheless, the transcriptomic analysis performed in the early stage of the 
differentiation process, highlighted a possible translational regulation involved in the regulation of 
the observed mitochondrial remodeling and driving the differentiation process. Following 
preliminary data and well described literature, the regulation of the eIF4E-4EBP1 axis by mTORC1 
appeared as an interesting and relevant regulatory axis linking mitochondrial remodeling and 
hepatogenic differentiation. However, according to the results obtained, the regulation of the eIF4E-
4EBP1 axis by mTORC1 would not have similar purpose than commonly described and expected in 
this case (enhancement of cell growth and global protein synthesis) and would have for objective to 
maintain a constant pool of active 4EBP1. A plausible hypothesis to explain these unexpected but 
interesting results is that this tight control of 4EBP1 could help to fine-tune the association of eIF4E 
with other eIF4F components in order to enhance eIF4G2 association with eIF3 and eIFA1 and 
promote cap-independent translational regulation of mitochondrial genes, supporting the 
mitochondrial remodeling and driving hepatogenic differentiation.   
  Altogether this hypothesis suggests that a potential translational regulation involving a transition 
from cap-dependent to cap-independent IRES-based translation does occur, this kind of regulation 
being already known to play a major role during the embryogenesis and thus to ensure developmental 
process (Yoffe et al., 2016). To confirm this hypothesis, characterization of the polysome-bound 
mRNAs in the early steps of the differentiation process will help to explore the putative translational 
regulation occurring during this cellular process and will allow for the identification of the main actors 
involved in this process.  
Although hepatocyte-like cells obtained at the end of the differentiation process are really 
immature, the molecular mechanisms described in this model are based on in vivo liver development. 
Therefore, despite the limited potential of these cells for cellular therapy and regenerative medicine 
(Ullah et al., 2015), the in vitro hepatogenic differentiation model remains useful for fundamental 
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Supplementary figure 1. Detailed protein abundance of mitochondrial markers and of eIF4F-related actors per donor.  Representation 
per donor of individual protein quantification of the blots shown in  Figure 13 (A), Figure 14 (B) and Figure 15 (C) and mean quantification of 










Supplementary figure 2. Differentiation efficiency control for the differentiation of donor 1 cells.  Morphology assessment (A), PAS 
staining (B) and mRNA markers (hepatic with TDO2, developmental with TBX3 and stemness marker with SOX9) (C) evaluation of donor 1 cells 





Supplementary figure 3. Differentiation efficiency control for the differentiation of donor 1 cells.  Morphology assessment (A), PAS 
staining (B) and mRNA markers (hepatic with TDO2, developmental with TBX3 and stemness marker with SOX9) (C) evaluation of donor 1 cells 
which underwent a differentiation process. The differentiation controlled here concern cells represented in Figure 16B. 
 
 
Supplementary figure 4. Negative controls for SUnSET experiment on donor 1 cells. Exp, Day 0 (D0) and Diff (D) and Undiff (ND) cells at 
day 2, 5, 9, 12, 15 and 22 were either exposed to 5 µg/mL puromycin (Puro) for 10 minutes (here Exp Puro was loaded on gel as a positive control), 
either to 20 µg/mL cycloheximide (CHX) for 30 minutes followed by exposition to puromycin + cycloheximide for 10 minutes or underwent 
medium replacement without puromycin. Cells were harvested and 10 µg of proteins were loaded on 10% acrylamide gel and puromycin and 












Supplementary figure 5. Primary and secondary antibodies controls for the immunofluorescence experiments on donor 1 cells. Exp 
cells were collected, seeded on coverslips and fixed. An immunofluorescence labelling was then performed with probing of eIF4E, 4EBP1 and 
TOM20 primary antibodies alone and of secondary antibodies mouse green (used for eIF4E marking) and rabbit green (used for 4EBP1 and 
TOM20 marking).  Nuclei were stained with DAPI. Scale bar = 100 μm. Negative control linked to the experiment showed on Figure 17. 
 
